Veterinary Drug terms — page 11 | HESTIA Glossary

Browse all 1,061 veterinary drug terms HESTIA uses to describe agricultural data — with definitions and synonyms. Free and open.

Glycopyrronium 3-[(2-Cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethylpyrrolidinium; NA
Glycylcyclines Tigecycline
Glyoxylic acid 2-Oxoacetic acid; Acetic acid, oxo-; 4-03-00-01489 (Beilstein Handbook Reference)
Gonadorelin Luteinizing hormone-releasing factor (swine); Gonadorelin; AY-24031
Gossypol 1,1',6,6',7,7'-Hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-[2,2'-binaphthalene]-8,8'-dicarboxaldehyde; gossypol; 303-45-7; (-)-Gossypol; 90141-22-3; Pogosin; (+)-Gossypol; Tash 1; (R)-(-)-Gossypol; (R)-Gossypol; racemic-Gossypol; (+-)-Gossypol; (+/-)-Gossypol; ssypol; NSC 56817; CCRIS 2689; AT101; C30H30O8; NSC56817; NSC 624336; BRN 1917878; CHEMBL51483; AI3-22957; 1,1',6,6',7,7'-Hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-[2,2'-binaphthalene]-8,8'-dicarbaldehyde; 20300-26-9; 7-(8-formyl-1,6,7-trihydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)-2,3,8-trihydroxy-6-methyl-4-propan-2-ylnaphthalene-1-carbaldehyde; 2,2'-bi[8-Formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene]; 2,2'-Bis(1,6,7-trihydroxy-3-methyl-5-isopropyl-8-aldehydonaphthalene); NSC-56817; NSC624336; Gossypol acetate; NSC-624336; NCGC00016423-03; CAS-303-45-7; ST065835; 8-Formyl-1,6,7-trihydroxy-5-isopropyl-3-methyl-2,2'-bisnaphthalene; DSSTox_CID_3110; DSSTox_RID_76879; DSSTox_GSID_23110; (2,2'-Binaphthalene)-8,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-, (-)-; (2,2'-Binaphthalene)-8,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-, (+)-; [2,2'-Binaphthalene]-8,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-; 4-08-00-03754 (Beilstein Handbook Reference); 7-[8-formyl-1,6,7-trihydroxy-3-methyl-5-(propan-2-yl)naphthalen-2-yl]-2,3,8-trihydroxy-6-methyl-4-(propan-2-yl)naphthalene-1-carbaldehyde; No Fertil; (2,2'-Binaphthalene)-8,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahyd; (2,2'-Binaphthalene)-8,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-; (2,2'-Binaphthalene)-8,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-; 7-(8-formyl-1,6,7-trihydroxy-5-isopropyl-3-methyl-2-naphthyl)-2,3,8-trihydroxy-4-isopropyl-6-methyl-naphthalene-1-carbaldehyde; 7-[8-formyl-1,6,7-trihydroxy-3-methyl-5-(methylethyl)(2-naphthyl)]-2,3,8-trihy droxy-6-methyl-4-(methylethyl)naphthalenecarbaldehyde; Gossypol Sodium Salt; Gissypol, (R)-; NSC-19048; Sodium Salt, Gossypol; Gossypol, (+)-Isomer; Gossypol, (-)-Isomer; SR-01000597521; Gossypol Dipotassium Salt; UNII-XNA7DR63CQ; BL 193; Gossypol, (+-)-Isomer; Dipotassium Salt, Gossypol; UNII-8DY2X8LXW4; UNII-KAV15B369O; Gossyol; HSDB 7872; Gossypol, 4; Prestwick_1031; Gossypol, (R)-; Gossypol, (S)-; Pogosin; AT101; Spectrum_000359; Spectrum_001521; Tocris-1964; SpecPlus_000602; acetic acid; 7-(8-formyl-1,6,7-trihydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)-2,3,8-trihydroxy-6-methyl-4-propan-2-ylnaphthalene-1-carbaldehyde; Prestwick0_000677; Prestwick1_000677; Prestwick2_000677; Prestwick3_000677; Spectrum2_001472; Spectrum2_001624; Spectrum3_001102; Spectrum3_001516; Spectrum4_000846; Spectrum4_001931; Spectrum5_000693; Spectrum5_001035; Gossypol from cotton seeds; XNA7DR63CQ; AT-101/GOSSYPOL; UPCMLD-DP103; NCIMech_000271; cid_3503; SCHEMBL3939; 8DY2X8LXW4; BSPBio_000773; BSPBio_002804; BSPBio_003191; KBioGR_001451; KBioGR_002303; KBioSS_000839; KBioSS_002001; MLS000028490; DivK1c_000173; DivK1c_006698; SPECTRUM1504019; SPBio_001423; SPBio_001687; SPBio_002694; BPBio1_000851; cid_227456; GTPL4204; KAV15B369O; DTXSID5023110; UPCMLD-DP103:001; UPCMLD-DP103:002; BDBM23223; BDBM46555; CTK8G0094; KBio1_000173; KBio1_001642; KBio2_000839; KBio2_002001; KBio2_003407; KBio2_004569; KBio2_005975; KBio2_007137; KBio3_002024; KBio3_002691; EX-A068; NINDS_000173; QBKSWRVVCFFDOT-UHFFFAOYSA-N; HMS1570G15; HMS2097G15; HMS3262J15; HMS3268O22; HMS3413L10; HMS3651C18; HMS3677L10; BCP03607; ZINC3775575; Tox21_110434; Tox21_500847; BL-193; BN0226; CCG-35400; MFCD00017352; NSC726190; NSC728875; SBB012338; STK063457; AKOS002140475; Tox21_110434_1; BCP9000332; CS-2106; DB13044; LMPR0103330002; LP00847; MCULE-2539927675; NSC-726190; NSC-728875; PXT0004725; SB17342; SDCCGSBI-0051726.P004; IDI1_000173; KS-0000183E; SMP2_000170; NCGC00016423-01; NCGC00016423-02; NCGC00016423-04; NCGC00016423-05; NCGC00016423-06; NCGC00016423-07; NCGC00016423-08; NCGC00016423-09; NCGC00016423-10; NCGC00016423-14; NCGC00016423-15; NCGC00025331-01; NCGC00025331-02; NCGC00025331-03; NCGC00025331-04; NCGC00025331-06; NCGC00025331-07; NCGC00261532-01; (2,2-Binaphthalene)-8,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-, (+-)-; 4CA-0193; AC-20251; AC-30274; AK148510; AS-55885; HY-13407; LS-43993; LS-43994; LS-43996; LS-43997; NCI60_001588; NCI60_004391; SC-79036; SMR000058386; BCP0726000183; DB-047766; AB00052921; FT-0631917; N2135; ST24036539; SW197103-2; V0195; A15004; C07667; S-7805; 156767-EP2284178A2; 156767-EP2284179A2; 303G457; C-23051; Q411882; J-017920; SR-01000597521-1; SR-01000597521-5; SR-01000597521-6; (+/-)-Gossypol from cotton seeds, >=95% (HPLC); BRD-K19295594-001-06-9; BRD-K19295594-001-10-1; BRD-K19295594-015-02-8; 8-Formyl-1,7-trihydroxy-5-isopropyl-3-methyl-2,2'-bisnaphthalene; (+/-)-2,2'-bis(8-Formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene); (-)-2,2'-Bis(1,6,7-trihydroxy-3-methyl-5-isopropyl-8-aldehydonaphthalene); (2,8'-dicarboxaldehyde, 1,1',6,6'7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-; [2,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-; (+)1,1',6,6',7,7'-Hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)[2,2'-binaphthalene]-8,8'-dicarboxaldehyde; (-)-1,1',6,6',7,7'-Hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-[2,2'-binaphthalene]-8,8'-dicarboxaldehyde; (-)-1,1',6,6',7,7'-Hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)[2,2'-binaphthalene]-8,8'-dicarboxaldehyde; [2,2'-Binaphthalene]-8,8'-dicarboxaldehyde,1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-, (2R)-; [2,8'-dicarboxaldehyde, 1,1',6,6',7,7'- hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-, (2R)-; [2,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1- methylethyl)-; [2,8'-dicarboxaldehyde, 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-; 1,1',6,6',7,7'-Hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-[2,2'-binaphthalene]-8,8'-dicarboxaldehyde; 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-2,2'-binaphthalene-8,8'-dicarbaldehyde; 1,1',6,6',7,7'-Hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)[2,2'-binaphthalene]-8,8'-dicarboxaldehyde; 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-di(propan-2-yl)-2,2'-binaphthalene-8,8'-dicarbaldehyde; 1,1',6,6',7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-2,2'-binaphthalene-8,8'-dicarbaldehyde; 1,1',6,6',7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-2,2'-binaphthyl-8,8'-dicarbaldehyde; 1,1',6,6',7,7'-Hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl[2,2'-binaphthalene]-8,8'-dicarbaldehyde; 1,1',6,6'-Tetrahydroxy-3,3'-dimethyl-5,5'-diisopropyl-8,8'-bis(hydroxymethylene)-2,2'-binaphthalene-7,7'(8H,8'H)-dione; 7-(8-Formyl-1,6,7-trihydroxy-3-methyl-5-(methylethyl)(2-naphthyl))-2,3,8-trihydroxy-6-methyl-4-(methylethyl)naphthalenecarbaldehyde; acetic acid; 7-(8-formyl-1,6,7-trihydroxy-3-methyl-5-propan-2-yl-2-naphthalenyl)-2,3,8-trihydroxy-6-methyl-4-propan-2-yl-1-naphthalenecarboxaldehyde; acetic acid; 7-(8-formyl-1,6,7-trihydroxy-5-isopropyl-3-methyl-2-naphthyl)-2,3,8-trihydroxy-4-isopropyl-6-methyl-naphthalene-1-carbaldehyde; ethanoic acid; 7-[8-methanoyl-3-methyl-1,6,7-tris(oxidanyl)-5-propan-2-yl-naphthalen-2-yl]-6-methyl-2,3,8-tris(oxidanyl)-4-propan-2-yl-naphthalene-1-carbaldehyde; Pogosin|||AT-101|||7-(8-Formyl-1,6,7-trihydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)-2,3,8-trihydroxy-6-methyl-4-propan-2-ylnaphthalene-1-carbaldehyde; Gossypol; 4-08-00-03754 (Beilstein Handbook Reference)
Gramine N,N-Dimethyl-1H-indole-3-methanamine; Gramine; 87-52-5; 3-(Dimethylaminomethyl)indole; Donaxine; Donaxin; Gramin; 1H-Indole-3-methanamine, N,N-dimethyl-; 1-(1H-indol-3-yl)-N,N-dimethylmethanamine; beta-Dimethylaminomethylindole; Indol-3-ylmethyldimethylamine; NSC 16892; (1H-indol-3-ylmethyl)dimethylamine; (1H-Indol-3-ylmethyl)-dimethyl-amine; (Indol-3-ylmethyl)dimethylamine; 3-[(Dimethylamino)methyl]indole; Donaxine; Gramine; UNII-FGQ8A78L14; Indolalkylamine der.; Gramine, 99%; 3-(N,N-Dimethylaminomethyl)indole; EINECS 201-749-8; Indole, 3-[(dimethylamino)methyl]-; MFCD00005629; N,N-Dimethyl-1H-indole-3-methanamine; AI3-52146; FGQ8A78L14; .beta.-Dimethylaminomethylindole; 1-(1H-indol-3-yl)-N,N-dimethyl-methanamine; OCDGBSUVYYVKQZ-UHFFFAOYSA-N; N,N-Dimethyl-1H-indole-3-methylamine; INDOLE, 3-((DIMETHYLAMINO)METHYL)-; 3-((N,N-Dimethylamino)methyl)indole (Gramine); 3-[Dimethylaminomethyl]indole; 3-((Dimethylamino)methyl)-Indole; 3-[(Dimethylamino)methyl]-Indole; Prestwick_245; PubChem8121; Enamine_005691; Prestwick0_000629; Prestwick1_000629; Prestwick2_000629; Prestwick3_000629; Oprea1_150946; SCHEMBL63578; b-(Dimethylaminomethyl)indole; BSPBio_000598; MLS002153919; beta -dimethylaminomethylindole; SCHEMBL445889; SPBio_002817; BPBio1_000658; CHEMBL254348; beta-(Dimethylaminomethyl)indole; DTXSID3058955; CHEBI:28948; CTK8B5338; KS-00000DHR; ZINC73686; HMS1410C15; HMS1569N20; HMS2096N20; HMS2268O03; HMS3651E18; 3-Dimethylaminomethylindol (gramin); ACT05054; HY-N0166; NSC16892; TNP00029; WLN: T56 BMJ D1N1&1; ANW-48354; BBL019761; CCG-46378; NSC-16892; s2304; SBB003799; STL146344; (1H-Indol-3-ylmethyl)-dimethylamine; AKOS001055234; MCULE-3643815953; RTR-027517; 1H-Indol-3-yl-N,N-dimethylmethanamine; CAS-87-52-5; IDI1_007926; NCGC00016343-01; NCGC00016343-02; NCGC00016343-03; NCGC00016343-04; NCGC00016343-05; NCGC00142364-01; NCGC00142364-02; NCGC00142364-03; (1H-indol-3-yl)-N,N-dimethylmethanamine; AC-15584; AS-11847; BR-30161; LS-82953; SC-07104; SMR000112262; ST023280; SY005107; 1H-Indol-3-yl-N,N-dimethylmethanamine #; AB0007640; AB1000351; DB-057006; TR-027517; 4CH-009343; CS-0007885; D0653; FT-0603302; N,N-Dimethyl-1H-indole-3-methanamine, 9CI; N-(1H-indol-3-ylmethyl)-N,N-dimethylamine; N2337; ST24028337; SW196552-2; C08304; S-5694; Q420118; SR-01000636080; SR-01000636080-1; SR-01000636080-4; BRD-K26005076-001-03-7; BRD-K26005076-001-06-0; InChI=1/C11H14N2/c1-13(2)8-9-7-12-11-6-4-3-5-10(9)11/h3-7,12H,8H2,1-2H; Gramine; AI3-52146
Griseofulvin (1'S,6'R)-7-Chloro-2',4,6-trimethoxy-6'-methylspiro[benzofuran-2(3H),1'-[2]cyclohexene]-3,4'-dione; Griseofulvin; 5-18-05-00150 (Beilstein Handbook Reference)
Guanidine guanidine; Iminourea; Aminomethanamidine; Carbamidine; Carbamamidine; Guanidin; Imidourea; Aminoformamidine; 113-00-8; UNII-JU58VJ6Y3B; Guanidine, free base; CHEBI:42820; EINECS 204-021-8; BRN 0506044; JU58VJ6Y3B; H2N-C(=NH)-NH2; ZRALSGWEFCBTJO-UHFFFAOYSA-N; Guanidine, Hydrochloride; Gu; GAI; HSDB 7603; CHEMBL821; Epitope ID:140101; NCIOpen2_007946; 4-03-00-00148 (Beilstein Handbook Reference); (NH2)2C=NH; GTPL4783; DTXSID0023117; CTK0H9021; ZINC8101126; BDBM50420178; STL223269; AKOS009031425; DB00536; MCULE-1152750770; LS-73193; SBI-0207070.P001; FT-0626820; C17349; AB00053583_04; 113G008; Q183309; A9B89FF5-2922-47CC-82CE-AC4157B624AE; 4-03-00-00148 (Beilstein Handbook Reference)
Guanine 2-Amino-1,7-dihydro-6H-purine-6-one; 2-Amino-1,7-dihydro-6H-purin-6-one; C.I. 75170
Guanosine guanosine; 118-00-3; guanine riboside; vernine; Guanozin; Guanosin; Inosine, 2-amino-; USAF CB-11; Vernine (VAN); L-GUANOSINE; 9-beta-D-Ribofuranosylguanine; Guanine-9-beta-D-ribofuranoside; beta-D-Ribofuranoside, guanine-9; Guanine, 9-beta-D-ribofuranosyl-; 2(3H)-Imino-9-beta-D-ribofuranosyl-9H-purin-6(1H)-one; Inosine, 2-amino- (VAN); Ribofuranoside, guanine-9, beta-D-; 2-Amino-1,9-dihydro-9-beta-D-ribofuranosyl-6H-purin-6-one; GUANINE-9:BETA-D-RIBOFURANOSIDE; Guo; AI3-52065; 2-Amino-9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-purin-6(9H)-one; MFCD00010182; NSC 19994; 9-beta-D-ribofuranosyl-guanine; Guanine, 9-beta-D-ribofuranosyl- (VAN); UNII-12133JR80S; CHEBI:16750; EINECS 204-227-8; 6H-Purin-6-one, 2-amino-1,9-dihydro-9-beta-D-ribofuranosyl-; 9-(beta-D-Ribofuranosyl)guanine; NYHBQMYGNKIUIF-UUOKFMHZSA-N; Guanosine, Anhydrous; Guanosine, 99%; 12133JR80S; ST057098; 26578-09-6; 2-AMINO-9-[(2R,3R,4S,5R)-3,4-DIHYDROXY-5-(HYDROXYMETHYL)OXOLAN-2-YL]-6,9-DIHYDRO-1H-PURIN-6-ONE; GR; 2-amino-9-beta-D-ribofuranosyl-1,9-dihydro-6H-purin-6-one; DL-Guanosine; 9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-aminohydropurin -6-one; 9-.beta.-D-ribofuranosylguanine; Ribonucleoside; Guanine, 9.beta.-d-ribofuranosyl-; .beta.-D-Ribofuranoside, guanine-9; 3h-guanosine; 2-amino-Inosine; 1odj; 2fqx; 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one; [3H]-guanosine; Inosine, 2-amino; AK-54659; guanosine-1-15N; guanosine-2-13C; guanosine-3-15N; guanosine-8-13C; guanosine-9-15N; guanosine-N-15N-; guanosine-1'-13C; PubChem9300; Guanosine, >=98%; guanosine-N,1-15N2; bmse000091; bmse001018; Epitope ID:141493; 9-b-D-ribofuranosyl-Guanine; SCHEMBL21217; 2(3H)-Imino-9-.beta.-D-ribofuranosyl-9H-purin-6(1H)-one; b-D-Ribofuranoside guanine-9; KSC175I9F; 9-beta-D-ribofuranosyl guanine; CHEMBL375655; GTPL4567; SGCUT00093; 9-bet.-D-Ribofuranosyl-guanine; Guanine-9-ss--D-ribofuranoside; SCHEMBL12212184; 9-(ss--D-Ribofuranosyl)guanine; CTK0H5492; Guanine-9-bet.-D-ribofuranoside; BIG2502; DTXSID00893055; guanosine-2-13C-N,1-15N2; ZX-AFC000652; 9-B-D-RIBOFURANOSYLGUANINE; 9-beta-delta-ribofuranosyl-Guanine; Guanine-9-.beta.-D-ribofuranoside; GUANOSINE ULTRA PURE 100G; 197227-95-5; 2-Amino-9-((2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-purin-6(9H)-one; beta-delta-Ribofuranoside guanine-9; Guanosine, >=97.0% (HPLC); HY-N0097; KS-000017MP; STR04471; to_000053; ZINC1550030; ZX-AT019677; ANW-17077; BBL033925; BDBM50366814; GE8690; guanosine-2-13C-N,1,3-15N3; OR4880; s2439; SBB003009; STK801927; AKOS005622500; AKOS007930368; AKOS015896931; AKOS032949764; 9-beta-D-ArabinofuranosylguanineHydrate; AM83933; CS-W020018; DB02857; MCULE-2959607047; Ribofuranoside, guanine-9, .beta.-D-; NCGC00142496-01; NCGC00142496-02; CC-29093; I890; LS-73951; SC-00504; AB0013923; AX8008614; DB-029875; FT-0626830; G0171; Guanosine, Vetec(TM) reagent grade, >=98%; A12000; C00387; EN300-204342; M-6019; Guanosine, suitable for cell culture, BioReagent; C-17812; Q422462; Q-201301; 2-Amino-9-bet.-D-ribofuranosyl-9H-purine-6-(1H)-one; 2-Amino-1,9-dihydro-9-b-D-ribofuranosyl-6H-purin-6-one; 2-Amino-9-.beta.-D-ribofuranosyl-9-H-purine-6(1H)-one; 2-Amino-1,9-dihydro-9.beta.-d-ribofuranosyl-6H-purin-6-one; 6H-Purin-6-one, 2-amino-1,9-dihydro-9-beta-D-ribofuranosyl; 2-Amino-1,9-dihydro-9-beta-delta-ribofuranosyl-6H-purin-6-one; 6H-Purin-6-one, 2-amino-1,9-dihydro-9-.beta.-D-ribofuranosyl-; 2-Amino-9-beta-D-ribofuranosyl-1,9-dihydro-6H-purin-6-one (Guanosine); 103654-69-9; 103654-70-2; 146849-94-7; 197227-93-3; 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-purin-6-one; 202933-46-8; 244769-87-7; 247226-75-1; 250586-91-5; 250586-97-1; AI3-52065
Guanosine-3'-monophosphate Guanylic acid; 3'-Guanylic acid; EINECS 204-202-1
Gylcopeptides/lipoglycopeptides Avoparcin; Dalbavancin; Oritavancin; Ramoplanin; Teicoplanin; Telavancin; Vancomycin
Hadacidin Hadacidin; N-FORMYL-N-HYDROXYGLYCINE; Hadacidine; 689-13-4; N-Formyl hydroxyaminoacetic acid; Asymmetrin; Hadacin; Nfhaa; N-hydroxyformamidoacetic acid; UNII-BFO5P1010A; Glycine,N-formyl-N-hydroxy-; 2-(N-Hydroxyformamido)acetic acid; N-formyl-N- hydroxyaminoacetic acid; GLYCINE, N-FORMYL-N-HYDROXY-; NSC 72962; BRN 1927168; BFO5P1010A; CHEMBL331373; CHEBI:43040; [formyl(hydroxy)amino]acetic acid; NSC 521778; hadicidine; Asymmetrin; Hadacidin; SCHEMBL2115651; DTXSID1043962; CTK5C8639; (Formyl-hydroxy-amino)-acetic acid; BCP31244; ZINC1482078; BDBM50149248; AKOS006278464; DB02109; LS-72659; NCI60_004270; ZINC000001482078; Q15303927; Asymmetrin
Haloperidol 4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone; haloperidol; 52-86-8; Haldol; Aloperidin; Serenace; Aloperidol; Brotopon; Eukystol; Einalon S; Aloperidolo; Galoperidol; Halojust; Halopoidol; Serenase; Serenelfi; Ulcolind; Uliolind; Vesalium; Halopal; Linton; Mixidol; Pernox; Sernas; Sernel; Dozic; Aldo; Lealgin compositum; Keselan; Peluces; Bioperidolo; Haldol Solutab; McN-JR-1625; Haloperidolum; Aloperidon; Fortunan; 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one; Aloperidolo [DCIT]; Aloperidolo [Italian]; Haloperidolum [INN-Latin]; NSC 170973; R 1625; R-1625; C21H23ClFNO2; 1-(3-p-Fluorobenzoylpropyl)-4-p-chlorophenyl-4-hydroxypiperidine; UNII-J6292F8L3D; CCRIS 1630; Haloperidol (Haldol); 4'-Fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone; 4'-Fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone; HSDB 3093; CHEMBL54; EINECS 200-155-6; Sigaperidol; Haldol (TN); NSC 615296; 4-(4-Hydroxy-4'-chloro-4-phenylpiperidino)-4'-fluorobutyrophenone; BRN 0331267; 1-Butanone, 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-; 4-(4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanone; 4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone; MLS000028450; CHEBI:5613; Halosten; LNEPOXFFQSENCJ-UHFFFAOYSA-N; 4-(4-(p-Chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone; 4-[4-(p-Chlorophenyl)-4-hydroxypiperidino]-4'-fluorobutyrophenone; J6292F8L3D; Butyrophenone, 4'-fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidino)-; 1-Butanone, 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-; 4-(4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one; NSC170973; NSC615296; NSC-170973; NSC-615296; CAS-52-86-8; NCGC00015500-10; Halidol; Halopidol; Pekuces; SMR000058303; 4'-Fluoro-4-(4-hydroxy-4-p-chlorophenylpiperidino)butyrophenone; Halol; 4-[4-(4-Chlorophenyl)-4-hydroxypiperidino]-4'-fluorobutyrophenone; gamma-(4-(p-Chlorophenyl)-4-hydroxypiperidino)-p-fluorbutyrophenone; 4-(4-(para-Chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone; Butyrophenone, 4-(4-(p-chlorophenyl)-4-hydroxypiperidino)-4'-fluoro-; gamma-(4-(p-Chlorophenyl)-4-hydroxypiperidino)-p-fluorobutyrophenone; 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one; DSSTox_CID_14150; DSSTox_RID_79117; DSSTox_GSID_34150; W-105791; Butyrophenone, 4-[4-(p-chlorophenyl)-4-hydroxypiperidino]-4'-fluoro-; gamma-(4-(p-Chlorophenyl)-4-hydroxpiperidino)-p-fluorbutyrophenone; SR-01000003076; Haloperidol [USAN:INN:BAN:JAN]; Duraperidol; 4'-Fluoro-4-[4-hydroxy-4-(4'-chlorophenyl)piperidino]butyrophenone; gamma-[4-(p-chlorophenyl)-4-hydroxypiperidino]-p-fluorobutyrophenone; 4-[4-(para-Chlorophenyl)-4-hydroxypiperidino]-4'-fluorobutyrophenone; Picroside-III; Haloperidol, 1; GMJ; Haloperidol, powder; Prestwick_250; Haloperidol [USAN:USP:INN:BAN:JAN]; MDMO-PPV; Spectrum_000861; Tocris-0931; Opera_ID_446; 4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-1-(4-fluoro-phenyl)-butan-1-one; propionate(HCl); Prestwick0_000115; Prestwick1_000115; Prestwick2_000115; Prestwick3_000115; Spectrum2_001268; Spectrum3_000448; Spectrum4_000570; Spectrum5_000788; Lopac-H-1512; Biomol-NT_000035; GTPL86; Probes1_000255; Probes2_000296; H 1512; SCHEMBL8264; Lopac0_000583; Oprea1_509923; BSPBio_000130; BSPBio_002096; KBioGR_000980; KBioGR_002390; KBioSS_001341; KBioSS_002395; 5-21-02-00377 (Beilstein Handbook Reference); 61788-97-4; MLS001146904; BIDD:GT0128; DivK1c_000654; SPECTRUM1500325; SPBio_001236; SPBio_002069; McM-JR-1625; BPBio1_000144; BPBio1_001231; Haloperidol (JP17/USP/INN); DTXSID4034150; BDBM21398; HMS502A16; KBio1_000654; KBio2_001341; KBio2_002390; KBio2_003909; KBio2_004958; KBio2_006477; KBio2_007526; KBio3_001316; KBio3_002869; LNEPOXFFQSENCJ-UHFFFAOYSA-; AOB5645; cMAP_000037; NINDS_000654; AC250; HMS1568G12; HMS1920D03; HMS2089M15; HMS2091J09; HMS2095G12; HMS2234P08; HMS3261F08; HMS3370H11; HMS3657I13; HMS3712G12; Pharmakon1600-01500325; ZINC537822; Haloperidol 1.0 mg/ml in Methanol; Tox21_110162; Tox21_300475; Tox21_500583; A0H334; BG0211; CCG-36042; CCG-39111; MFCD00051423; NSC757054; STL417208; 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)butan-1-one; AKOS000280660; Tox21_110162_1; API0002885; CS-1971; DB00502; LP00583; MCULE-3693790133; NSC-757054; SDCCGSBI-0050565.P005; IDI1_000654; MRF-0000027; QTL1_000042; WLN: T6NTJ A3VR DF& DQ DR DG; NCGC00015500-01; NCGC00015500-02; NCGC00015500-03; NCGC00015500-04; NCGC00015500-05; NCGC00015500-06; NCGC00015500-07; NCGC00015500-08; NCGC00015500-09; NCGC00015500-11; NCGC00015500-12; NCGC00015500-13; NCGC00015500-14; NCGC00015500-15; NCGC00015500-16; NCGC00015500-17; NCGC00015500-19; NCGC00016234-01; NCGC00023875-02; NCGC00023875-04; NCGC00023875-05; NCGC00023875-06; NCGC00023875-07; NCGC00023875-08; NCGC00023875-09; NCGC00254503-01; NCGC00261268-01; 177716-59-5; AC-19691; CC-16450; HY-14538; LS-48311; SC-81035; ACM1189986591; SBI-0050565.P004; AB2000375; SC 170973; TR-018722; AB00052008; EU-0100583; FT-0669100; FT-0697842; N1910; S1920; ST50319916; SW196557-4; W0039; 4763-EP2269989A1; 4763-EP2269990A1; 4763-EP2272537A2; 4763-EP2272972A1; 4763-EP2272973A1; 4763-EP2275420A1; 4763-EP2277872A1; 4763-EP2277876A1; 4763-EP2292614A1; 4763-EP2295061A1; 4763-EP2295412A1; 4763-EP2295413A1; 4763-EP2295439A1; 4763-EP2298731A1; 4763-EP2298776A1; 4763-EP2305260A1; 4763-EP2308867A2; 4763-EP2308870A2; 4763-EP2311801A1; 4763-EP2311803A1; 4763-EP2311824A1; 4763-EP2311837A1; 4763-EP2316834A1; C01814; D00136; VU0239704-10; AB00052008-21; AB00052008-22; AB00052008_23; AB00052008_24; C-35402; L000288; Q251347; SR-01000003076-2; SR-01000003076-8; BRD-K67783091-001-04-8; BRD-K67783091-001-05-5; BRD-K67783091-003-03-6; SR-01000003076-11; Haloperidol, European Pharmacopoeia (EP) Reference Standard; Poly[2-methoxy-5-(3,7-dimethyoctyoxyl)-1,4-phenylenevinylene]; .gamma.-[4-(p-Chlorphenyl)-4-hydroxpiperidino]-p-fluorbutyrophenone; Haloperidol, United States Pharmacopeia (USP) Reference Standard; .gamma.-(4-(p-Chlorophenyl)-4-hydroxpiperidino)-p-fluorbutyrophenone; 4-[4-(4-chlorophenyl)-4-hydroxypiperidyl]-1-(4-fluorophenyl)butan-1-one; Haloperidol, Pharmaceutical Secondary Standard; Certified Reference Material; 4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl) -1-butanone; Haloperidol for peak identification, European Pharmacopoeia (EP) Reference Standard; Haloperidol for system suitability, European Pharmacopoeia (EP) Reference Standard; Haloperidol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; InChI=1/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2; Haloperidol; R 1625
Halothane 2-Bromo-2-chloro-1,1,1-trifluoroethane; halothane; 151-67-7; Fluothane; Narcotane; 2-BROMO-2-CHLORO-1,1,1-TRIFLUOROETHANE; Rhodialothan; Narcotan; Anestan; Bromochlorotrifluoroethane; Fluorotane; Ftuorotan; Phthorothanum; Ftorotan; Halothan; Narkotan; Fluktan; Halotan; Halsan; Halan; Chalothane; Halotano; Alotano; Ftorotan [Russian]; Alotano [DCIT]; Freon 123B1; Bromchlortrifluoraethanum; 1,1,1-Trifluoro-2-chloro-2-bromoethane; 1-Bromo-1-chloro-2,2,2-trifluoroethane; Halothanum; Halotano [INN-Spanish]; Halothanum [INN-Latin]; 1,1,1-Trifluoro-2-bromo-2-chloroethane; 2,2,2-Trifluoro-1-chloro-1-bromoethane; Narcotann ne-spofa; Narcotann NE-spofa [Russian]; Ethane, 2-bromo-2-chloro-1,1,1-trifluoro-; CF3CHClBr; Ethane, bromochlorotrifluoro-; 2-Brom-2-chlor-1,1,1-trifluorethan; NSC 143490; CCRIS 6244; CHEBI:5615; HSDB 6753; Halothane [Anaesthetics, volatile]; Ethane, 1-bromo-1-chloro-2,2,2-trifluoro-; EINECS 205-796-5; MFCD00009602; CHEMBL931; BRN 1736947; BCQZXOMGPXTTIC-UHFFFAOYSA-N; (+-)-2-Bromo-2-chloro-1,1,1-trifluoroethane; NCGC00090868-01; DSSTox_CID_5371; DSSTox_RID_77767; DSSTox_GSID_25371; Ethane, 2-bromo-2-chloro-1,1,1-trifluoro-, (+-)-; Fluothane (TN); Halothane [INN:BAN:JAN]; CAS-151-67-7; C2HBrClF3; Halothane [USP:INN:BAN:JAN]; WLN: GYEXFFF; ACMC-1BHQY; Ethane,1,1-trifluoro-; Epitope ID:150925; (.+/-.))-Halothane; SCHEMBL25588; Halothane (JP17/USP/INN); GTPL2401; DTXSID4025371; BCQZXOMGPXTTIC-UHFFFAOYSA-; CTK4C7172; HMS2094K17; Pharmakon1600-01505434; HY-B1010; Tox21_111033; Tox21_200850; BDBM50112212; LS-881; NSC143490; NSC760138; s4570; AKOS006227959; Tox21_111033_1; 1,1-Trifluoro-2-bromo-2-chloroethane; 1,1-Trifluoro-2-chloro-2-bromoethane; 2,2-Trifluoro-1-chloro-1-bromoethane; 2-Bromo-2-chloro-1,1-trifluoroethane; CCG-213438; CS-4523; DB01159; NSC-143490; NSC-760138; 1-bromo-1-chloro-2,2,2-trifluorethane; NCGC00090868-02; NCGC00090868-03; NCGC00090868-05; NCGC00258404-01; SBI-0206928.P001; DB-043111; TC-170891; Ethane,2-bromo-2-chloro-1,1,1-trifluoro-; FT-0626853; 2979-EP2269610A2; 2979-EP2277848A1; 2979-EP2280006A1; 2979-EP2281813A1; 2979-EP2284160A1; 2979-EP2289510A1; 2979-EP2292589A1; 2979-EP2298735A1; 2979-EP2298767A1; 2979-EP2314587A1; 2979-EP2316457A1; 2979-EP2316458A1; 2979-EP2316825A1; 2979-EP2316826A1; 2979-EP2316827A1; 2979-EP2316828A1; C07515; D00542; Q32921; 1-Bromo-1-chloro-2,2,2-trifluoroethane, 99%; AB01563314_01; SR-05000001969; 2-Bromo-2-chloro-1,1,1-trifluoroethane, >=99%; InChI=1/C2HBrClF3/c3-1(4)2(5,6)7/h1H; J-008834; SR-05000001969-1; 2-Bromo-2-chloro-1,1,1-trifluoroethane, >=99.0% (GC); Halothane, United States Pharmacopeia (USP) Reference Standard; 4-01-00-00156 (Beilstein Handbook Reference)
Heptanoic acid 4-02-00-00958 (Beilstein Handbook Reference)
Hesperetin 5,7,3'-Trihydroxy-4'-methoxyflavanone; hesperetin; Hesperitin; 520-33-2; 3',5,7-Trihydroxy-4'-methoxyflavanone; YSO2; (-)-hesperetin; Cyanidanon 4'-methyl ether 1626; 5,7,3'-Trihydroxy-4'-methoxyflavanone; (S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one; NSC 57654; Prestwick_908; UNII-Q9Q3D557F1; (-)-(S)-hesperetin; EINECS 208-290-2; CHEBI:28230; AIONOLUJZLIMTK-AWEZNQCLSA-N; Q9Q3D557F1; (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydro-4H-chromen-4-one; (S)-2,3-Dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone; MFCD00075646; (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one; (2s)-5,7-Dihydroxy-2-(3-Hydroxy-4-Methoxyphenyl)-2,3-Dihydro-4h-1-Benzopyran-4-One; (S)-2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-, (S)-; Flavanone, 3',5,7-trihydroxy-4'-methoxy- (VAN) (8CI); Hesperitine; NSC-57654; AK327599; TNP00238; (+/-)-Hesperetin; Spectrum_000181; Prestwick0_000124; Prestwick1_000124; Prestwick2_000124; Prestwick3_000124; Spectrum2_001793; Spectrum3_001104; Spectrum4_001935; Spectrum5_000683; (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydrochromen-4-one; Oprea1_828704; SCHEMBL39833; BSPBio_000168; BSPBio_002808; KBioGR_002311; KBioSS_000661; SPECTRUM310012; MLS002154205; BIDD:ER0512; DivK1c_001039; SPBio_001745; SPBio_002107; BPBio1_000186; CHEMBL399121; DTXSID4022319; BCBcMAP01_000087; BDBM23418; HMS503O19; KBio1_001039; KBio2_000661; KBio2_003229; KBio2_005797; KBio3_002028; ZINC39092; NINDS_001039; HMS1568I10; HMS2095I10; HMS2230M09; HMS3649H22; (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxy-phenyl)chroman-4-one; BCP28273; HY-N0168; KS-00000KM5; BBL104011; CCG-38441; LMPK12140003; s2308; SBB005936; STL557824; AKOS016339567; AC-7970; DB01094; KS-5307; SDCCGMLS-0066605.P001; ACM41001905; IDI1_001039; SMP1_000148; NCGC00016482-01; NCGC00016482-02; NCGC00016482-03; NCGC00016482-04; NCGC00142415-01; NCGC00142415-02; 5,7, 3'-Trihydroxy-4'-methoxyflavanone; CAS-520-33-2; SMR001233491; ST055624; LS-185786; FT-0626940; N1856; SW197026-2; C01709; Q411310; SR-01000946723; Flavanone, 3',5,7-trihydroxy-4'-methoxy- (VAN); SR-01000946723-1; BRD-K30553453-001-05-8; BRD-K30553453-001-08-2; Flavanone, 3',5, 7-trihydroxy-4'-methoxy- (VAN); (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-3,4-dihydro-2H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one,2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-, (2S)-; (2S)-5,7-Dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydro-4H-1-benzopyran-4-one (Hesperetin); 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-, (S)- (9CI); 6JP; Hesperetin; EINECS 208-290-2
Hesperidin Hesperetin; hesperetin; Hesperitin; 520-33-2; 3',5,7-Trihydroxy-4'-methoxyflavanone; YSO2; (-)-hesperetin; Cyanidanon 4'-methyl ether 1626; 5,7,3'-Trihydroxy-4'-methoxyflavanone; (S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one; NSC 57654; Prestwick_908; UNII-Q9Q3D557F1; (-)-(S)-hesperetin; EINECS 208-290-2; CHEBI:28230; AIONOLUJZLIMTK-AWEZNQCLSA-N; Q9Q3D557F1; (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydro-4H-chromen-4-one; (S)-2,3-Dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone; MFCD00075646; (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one; (2s)-5,7-Dihydroxy-2-(3-Hydroxy-4-Methoxyphenyl)-2,3-Dihydro-4h-1-Benzopyran-4-One; (S)-2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-, (S)-; Flavanone, 3',5,7-trihydroxy-4'-methoxy- (VAN) (8CI); Hesperitine; NSC-57654; AK327599; TNP00238; (+/-)-Hesperetin; Spectrum_000181; Prestwick0_000124; Prestwick1_000124; Prestwick2_000124; Prestwick3_000124; Spectrum2_001793; Spectrum3_001104; Spectrum4_001935; Spectrum5_000683; (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydrochromen-4-one; Oprea1_828704; SCHEMBL39833; BSPBio_000168; BSPBio_002808; KBioGR_002311; KBioSS_000661; SPECTRUM310012; MLS002154205; BIDD:ER0512; DivK1c_001039; SPBio_001745; SPBio_002107; BPBio1_000186; CHEMBL399121; DTXSID4022319; BCBcMAP01_000087; BDBM23418; HMS503O19; KBio1_001039; KBio2_000661; KBio2_003229; KBio2_005797; KBio3_002028; ZINC39092; NINDS_001039; HMS1568I10; HMS2095I10; HMS2230M09; HMS3649H22; (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxy-phenyl)chroman-4-one; BCP28273; HY-N0168; KS-00000KM5; BBL104011; CCG-38441; LMPK12140003; s2308; SBB005936; STL557824; AKOS016339567; AC-7970; DB01094; KS-5307; SDCCGMLS-0066605.P001; ACM41001905; IDI1_001039; SMP1_000148; NCGC00016482-01; NCGC00016482-02; NCGC00016482-03; NCGC00016482-04; NCGC00142415-01; NCGC00142415-02; 5,7, 3'-Trihydroxy-4'-methoxyflavanone; CAS-520-33-2; SMR001233491; ST055624; LS-185786; FT-0626940; N1856; SW197026-2; C01709; Q411310; SR-01000946723; Flavanone, 3',5,7-trihydroxy-4'-methoxy- (VAN); SR-01000946723-1; BRD-K30553453-001-05-8; BRD-K30553453-001-08-2; Flavanone, 3',5, 7-trihydroxy-4'-methoxy- (VAN); (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-3,4-dihydro-2H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one,2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-, (2S)-; (2S)-5,7-Dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydro-4H-1-benzopyran-4-one (Hesperetin); 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-, (S)- (9CI); 6JP; Hesperidin; 5-18-05-00218 (Beilstein Handbook Reference)
Hexachloro-2,5-cyclohexadien-1-one 2,3,4,4,5,6-Hexachloro-2,5-cyclohexadien-1-one; Hexachlorfenol; USAF DO-65; Hexachlorfenol [Czech]; Hexachlorocyclohexadienone; 599-52-0; hexachlorocyclohexa-2,5-dien-1-one; Hexachloro-2,5-cyclohexadien-1-one; 2,3,4,4,5,6-hexachlorocyclohexa-2,5-dien-1-one; Hexachloro-2,5-cyclohexadienone; 2,5-Cyclohexadien-1-one, 2,3,4,4,5,6-hexachloro-; NSC 2131; NSC 2868; BRN 2055056; AI3-00152; 2,3,4,4,5,6-Hexachloro-2,5-cyclohexadienone; Phenol, hexachloro-; 2,3,4,4,5,6-Hexachlorcyklohexa-2,5-dien-1-on [Czech]; 2, 2,3,4,4,5,6-hexachloro-; WLN: L6V DHJ BG CG DG DG EG FG; 2,4,4,5,6-Hexachloro-2,5-cyclohexadienone; 2,4,4,5,6-Hexachlorcyklohexa-2,5-dien-1-on; 2,3,4,4,5,6-Hexachlorcyklohexa-2,5-dien-1-on; 4-07-00-00289 (Beilstein Handbook Reference); 2,3,4,4,5,6-Hexachloro-2,5-cyclohexadien-1-one; SCHEMBL5025868; CTK5B0746; DTXSID10208611; NSC2131; NSC2868; SLKWROUNLHVIIQ-UHFFFAOYSA-N; NSC-2131; NSC-2868; ZINC1577169; LS-56328; Q5748689; 2,5-Cyclohexadien-1-one, 2,3,4,4,5,6-hexachloro-; 4-07-00-00289 (Beilstein Handbook Reference)
Hexamethylene diamine 1,6-Hexanediamine; 1,6-Hexanediamine; 1,6-Diaminohexane; Hexamethylenediamine; 124-09-4; HEXANE-1,6-DIAMINE; HMDA; 1,6-Hexylenediamine; 1,6-Hexamethylenediamine; 1,6-Diamino-n-hexane; Hexylenediamine; HEXAMETHYLENE DIAMINE; diaminohexane; 1,6-Hexanediamine (solution); Hexane, 1,6-diamino-; UNII-ZRA5J5B2QW; HEX-NH2; NCI-C61405; NSC 9257; CCRIS 6224; H2N(CH2)6NH2; HSDB 189; EINECS 204-679-6; MFCD00008243; UN1783; UN2280; ZRA5J5B2QW; Hexamethylenediamine solution; BRN 1098307; AI3-37283; CHEMBL303004; CHEBI:39618; NAQMVNRVTILPCV-UHFFFAOYSA-N; DSSTox_CID_4922; DSSTox_RID_77583; DSSTox_GSID_24922; 1,6-Hexanediamine, 99.5+%; 16D; CAS-124-09-4; 1,6-Hexanediamine, 60 wt % aqueous soln.; Amides, vegetable-oil, N,N'-hexanediylbis-; 1,6diaminohexane; 6-aminohexylamine; 1,6 diaminohexane; 1,6 hexanediamine; 1.6-diaminohexane; 1,6-diamino hexane; ACMC-209aqn; 1,6-hexamethylene diamine; Hexamethylenediamine, solid; Hexamethylenediamine, 98%; EC 204-679-6; WLN: Z6Z; Hexamethylene diamine, solid; NCIOpen2_002722; SCHEMBL15085; Hexamethylenediamine, solution; 4-04-00-01320 (Beilstein Handbook Reference); 73398-58-0; KSC175C6D; UN 1783 (Salt/Mix); 1,6-Hexandiamine, vegetable oil fatty acids diamide; Hexamethylene diamine, solution; Hexamethylenediamine, solution [UN1783] [Corrosive]; SCHEMBL7090279; DTXSID5024922; CTK0H5161; KS-00000WQU; NSC9257; EBD28825; NSC-9257; ZINC1543408; Tox21_202088; Tox21_303123; ANW-18189; BBL027705; BDBM50323740; LS-692; SBB059999; STL281875; AKOS000118875; DB03260; MCULE-3766020930; RTR-003749; UN 2280; 1,6-Diaminohexane; Hexamethylenediamine; NCGC00091677-01; NCGC00091677-02; NCGC00257104-01; NCGC00259637-01; BP-21415; VS-08580; Hexamethylenediamine, technical grade, 70%; TR-003749; D0095; FT-0083167; FT-0606994; ST45255381; 131132-EP2270113A1; 131132-EP2272935A1; 131132-EP2295399A2; 131132-EP2377846A1; AG-690/11351767; Hexamethylenediamine, SAJ first grade, >=98.0%; Hexamethylenediamine, solid [UN2280] [Corrosive]; Q424936; Hexamethylenediamine, solid [UN2280] [Corrosive]; J-504038; 1,6-HEXANEDIAMINE (SEE ALSO: 6055-52-3); Hexamethylenediamine, solution [UN1783] [Corrosive]; F1791-1256; Z966690422; InChI=1/C6H16N2/c7-5-3-1-2-4-6-8/h1-8H; 1,6-Diaminohexane; 4-04-00-01320 (Beilstein Handbook Reference)
Hexane-1,6-diol 1,6-Hexanediol; 1,6-HEXANEDIOL; Hexane-1,6-diol; 629-11-8; Hexamethylene glycol; 1,6-Dihydroxyhexane; Hexamethylenediol; alpha,omega-Hexanediol; .alpha.,.omega.-Hexanediol; UNII-ZIA319275I; CCRIS 8982; 6-hydroxy-1-hexanol; HSDB 6488; NSC 508; EINECS 211-074-0; 1,6-Hexanediol, 97%; BRN 1633461; AI3-03307; CHEBI:43078; XXMIOPMDWAUFGU-UHFFFAOYSA-N; ZIA319275I; HEZ; 1,6-Hexylene Glycol; 1,6hexanediol; 1,6 hexanediol; 1.6-hexanediol; 1,6-hexandiol; 1.6-hexandiol; .omega.-Hexanediol; 1,6-hexane diol; 1,6-hexan-diol; hexan-1,6-diol; Hexanediol-(1,6); ACMC-1AWZJ; DSSTox_CID_7265; 1,6-Hexanediol, 99%; EC 211-074-0; WLN: Q6Q; DSSTox_RID_78376; HO(CH2)6OH; DSSTox_GSID_27265; SCHEMBL15343; KSC354A3N; CHEMBL458616; NSC508; DTXSID1027265; CTK2F4036; NSC-508; KS-00000XA4; ZINC1555566; Tox21_200450; ANW-34445; MFCD00002985; SBB059915; AKOS003242194; CS-W011221; DB02210; MCULE-8817570517; RTR-021653; TRA0037961; NCGC00248624-01; NCGC00258004-01; AK116669; AS-12686; BP-21412; CAS-629-11-8; LS-75084; SC-26075; DB-027344; ST2419414; TR-021653; 601-EP2308857A1; 601-EP2372017A1; FT-0607014; ST51046183; 55472-EP2270101A1; 55472-EP2284165A1; 55472-EP2301919A1; 55472-EP2308865A1; 55472-EP2371805A1; 55472-EP2373601A2; 1,6-Hexanediol solution, BioUltra, ~6 M in H2O; 1,6-Hexanediol, >=99% C6-Dioles basis (GC); A834086; Q161563; J-504039; F0001-1701; InChI=1/C6H14O2/c7-5-3-1-2-4-6-8/h7-8H,1-6H; Hexamethylene glycol; 4-01-00-02556 (Beilstein Handbook Reference)
Hexestrol (R*,S*)-4,4'-(1,2-Diethyl-1,2-ethanediyl)bisphenol; hexestrol; Cycloestrol; Sinestrol; Phenol, 4,4'-(1,2-diethylethylene)di-, meso-; meso-Vitestrol; NSC-9894; Phenol, 4,4'-(1,2-diethyl-1,2-ethanediyl)bis-, (R*,S*)-; Dihydrostilbestrol, meso; Dihydrodiethylstilbestrol, meso; PBBGSZCBWVPOOL-QNSVNVJESA-N; Hexane, 3,4-bis(p-hydroxyphenyl)-, meso; .gamma.,.delta.-Di(p-hydroxyphenyl)-hexane, meso; 4,4'-(1,2-Diethylethylene)bis(phenol), (R*,S*)-; 4,4'-Dihydroxy-.gamma.,.delta.-diphenylhexane, meso; Bibenzyl, .alpha.,.alpha.'-diethyl-4,4'-dihydroxy-; (R*,S*)-4,4'-(1,2-diethyl-1,2-ethanediyl)bisphenol; 4,4'-Dihydroxy-.alpha.,.beta.-diethyldiphenylethane, meso; Phenol, 4,4'-(1,2-diethyl-1,2-ethylenediyl)bis-, (R*,S*)-; Hexestrol; meso-3,4-Bis(p-hydroxyphenyl)-n-hexane
Hexobarbital 5-(1-Cyclohexen-1-yl)-1,5-dimethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; Hexobarbital; Hexobarbitone; Methylhexabital; Methexenyl; Evipal; Evipan; Barbidorm; Cyclopan; Enhexymal; Noctivane; Sombucaps; Sombulex; Somnalert; Citopan; 56-29-1; Methylhexabarbital; Cyclonal; Hexabarbital; Narcosan; Citodon; Dorico; Hexanastab oral; Hexenal (barbiturate); Esobarbitale; Hexobarbitalum; Hexobarbitonum; Enhexymalum; Hexobarbital (VAN); Esobarbitale [DCIT]; 5-(1-CYCLOHEXEN-1-YL)-1,5-DIMETHYLBARBITURIC ACID; Esobarbitale [Italian]; Hexobarbitalum [INN-Latin]; Sodium hexobarbital; N-Methyl-5-cyclohexenyl-5-methylbarbituric acid; 1,5-Dimethyl-5-(1-cyclohexenyl)barbituric acid; NSC 71929; 5-(1-Cyclohexen-1-yl)-1,5-dimethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-(1-Cyclohexenyl-1)-1-methyl-5-methylbarbituric acid; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-cyclohexen-1-yl)-1,5-dimethyl-; EINECS 200-264-9; Barbituric acid, 5-(1-cyclohexen-1-yl)-1,5-dimethyl-; AI3-61892; CHEBI:5706; 5-(cyclohexen-1-yl)-1,5-dimethyl-1,3-diazinane-2,4,6-trione; UYXAWHWODHRRMR-UHFFFAOYSA-N; 5-(cyclohex-1-en-1-yl)-1,5-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-(delta-1,2-Cyclohexenyl)-5-methyl-N-methyl-barbitursaeure [German]; NCGC00159430-02; NCGC00159430-03; NCGC00159430-04; DSSTox_CID_3122; DSSTox_RID_76882; DSSTox_GSID_23122; 5-(CYCLOHEX-1-ENYL)-1,5-DIMETHYL-BARBITURIC ACID; 5-Cyclohex-1-enyl-1,5-dimethyl-pyrimidine-2,4,6-trione; 5-(.delta.-1,2-cyclohexenyl)-5-methyl-N-methyl-barbitursaeure; 5-cyclohexenyl-1,5-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione; Hexobarbital [INN:JAN]; CAS-56-29-1; Hexobarbital (JAN/INN); Hexobarbital [USP:INN:BAN:JAN]; (+/-)-Hexobarbital; 5-(delta-1,2-cyclohexenyl)-5-methyl-N-methyl-barbitursaeure; Barbituric acid,5-dimethyl-; CHEMBL7728; Oprea1_350917; SCHEMBL29821; MLS001143909; DTXSID9023122; CTK7H5490; HMS2272K03; NSC71929; Hexobarbital 1.0 mg/ml in Methanol; Tox21_111661; Tox21_111662; NSC-71929; STK696034; 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-cyclohexen-1-yl)-1,5-dimethyl; 5-cyclohex-1-en-1-yl-1,5-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione; 5-cyclohex-1-en-1-yl-2-hydroxy-1,5-dimethylpyrimidine-4,6(1H,5H)-dione; AKOS000355976; AKOS016347605; Tox21_111661_1; API0008991; DB01355; MCULE-5992814246; VA10872; AC-16076; LS-24041; SMR000473348; 5-cyclohexenyl-3,5-dimethylbarbituric acid; DB-052887; FT-0631247; WLN: T6VMVNV FHJ D1 F1 F- AL6UTJ; C11723; D01071; 5-(Cyclohexen-1-yl)-1,5-dimethylbarbitursaeure; 5-(Cyclohexen-1-yl)-1,5-dimethylbarbituric acid; Q421183; 5-(cyclohex-1-en-1-yl)-1,5-dimethyl-1,3-diazinane-2,4,6-trione; Hexobarbital, United States Pharmacopeia (USP) Reference Standard; 2,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-cyclohexen-1-yl)-1,5-dimethyl-; 5-(1-cyclohexenyl)-1,5-dimethyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-(Cyclohex-1-en-1-yl)-2-hydroxy-1,5-dimethylpyrimidine-4,6(1H,5H)-dione; Hexobarbital solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; Hexobarbital; AI3-61892
Hinokitiol 2-Hydroxy-4-(1-methylethyl)-2,4,6-cycloheptatrien-1-one; hinokitiol; beta-Thujaplicin; 499-44-5; 4-Isopropyltropolone; Hinokitol; beta-Thujaplicine; THUJAPLICIN, BETA; Tropolone, 4-isopropyl-; 2-Hydroxy-4-isopropyl-2,4,6-cycloheptatrien-1-one; beta-Isopropyltropolon; Isopropyltropolone; 2,4,6-Cycloheptatrien-1-one, 2-hydroxy-4-(1-methylethyl)-; .beta.-Thujaplicin; beta-Isopropyltropolone; .beta.-Isopropyltropolon; UNII-U5335D6EBI; NSC 18804; .beta.-Thujaplicine; 2-hydroxy-4-(propan-2-yl)cyclohepta-2,4,6-trien-1-one; NSC18804; EINECS 207-880-7; 2-Hydroxy-4-isopropyl-2,4,6-cyclohepta-2,4,6-trien-1-one; 2-Hydroxy-4-isopropylcyclohepta-2,4,6-trien-1-one; BRN 2045206; CHEMBL48310; AI3-28398; MLS001048906; Hinokitiol 4-Isopropyltropolone; U5335D6EBI; 2-Hydroxy-4-(1-methylethyl)-2,4,6-cycloheptatrien-1-one; CHEBI:10447; FUWUEFKEXZQKKA-UHFFFAOYSA-N; 2-hydroxy-4-isopropyl- 2,4,6-cycloheptatriene-1-one; SMR000387099; 2,4,6-CYCLOHEPTATRIEN-1-ONE, 2-HYDROXY-4-ISOPROPYL-; ss-Thujaplicine; b-Thujaplicin; beta -thujaplicin; beta -thujaplicine; beta.-Thujaplicine; 6-Isopropyl-tropolon; Thujaplicin, .beta.; 4-isopropyl-tropolone; beta -isopropyltropolon; PubChem11045; beta-Thujaplicin, 99%; 4(6)-Isopropyltropolone; NCIMech_000141; cid_3611; BSPBio_001025; KBioGR_000365; KBioSS_000365; 4-08-00-00488 (Beilstein Handbook Reference); BIDD:ER0491; SCHEMBL158795; SPECTRUM1505160; 2-hydroxy-6-isopropyl-cyclohepta-2,4,6-trien-1-one; 2-hydroxy-6-propan-2-ylcyclohepta-2,4,6-trien-1-one; DTXSID6043911; BDBM79632; CTK4J1829; FUWUEFKEXZQKKA-UHFFFAOYSA-; KBio2_000365; KBio2_002933; KBio2_005501; KBio3_000709; KBio3_000710; WLN: L7VJ BQ DY1&1; 2,4,6-Cycloheptatrien-1-one,2-hydroxy-4-(1-methylethyl)-; Bio2_000343; Bio2_000823; HMS1362C07; HMS1792C07; HMS1990C07; HMS2269D23; HMS3403C07; HY-B2230; ANW-41605; BBL036671; BDBM50330794; CCG-35378; CH-502; CT-820; NSC-18804; s4771; STL559050; ZINC95911093; AKOS015895184; CS-7724; KS-5297; IDI1_002098; QTL1_000044; NCGC00094565-01; NCGC00094565-02; NCGC00094565-03; NCGC00094565-04; NCGC00179338-01; AK687750; LS-56183; NCI60_001565; DB-051705; TR-030623; FT-0603426; V0549; C09904; D04876; K-9254; beta-Thujaplicin, SAJ special grade, >=99.0%; 2-Hydroxy-4-isopropyl-2,6-cycloheptatrien-1-one; 2-Hydroxy-4-isopropyl-cyclohepta-2,4,6-trienone; 2-Hydroxy-6-isopropyl-2,4,6-cycloheptene-1-one; 499H445; SR-01000737397; 2,6-Cycloheptatrien-1-one, 2-hydroxy-4-isopropyl-; 2-hydroxy-4-isopropyl-cyclohepta2,4,6-trien-1-one; J-521461; Q2705171; SR-01000737397-2; 2-Hydroxy-4-isopropyl-2,4, 6-cycloheptatrien-1-one; 2-Hydroxy-4-isopropyl-cyclohepta-2,4,6-trien-1-one; BRD-K37691127-001-02-2; 2-hydroxy-6-propan-2-yl-1-cyclohepta-2,4,6-trienone; 2-oxidanyl-6-propan-2-yl-cyclohepta-2,4,6-trien-1-one; Z2671848059; 2,6-Cycloheptatrien-1-one, 2-hydroxy-4-(1-methylethyl)-; (2E,4Z,6Z)-2-hydroxy-4-isopropylcyclohepta-2,4,6-trienone; 2-Hydroxy-4(6)-(1-methylethyl)-2,4,6-cycloheptatrien-1-one, 9CI; InChI=1/C10H12O2/c1-7(2)8-4-3-5-9(11)10(12)6-8/h3-7H,1-2H3,(H,11,12); 2,4,6-Cycloheptatrien-1-one, 2-hydroxy-4-(1-methylethyl)-; 4-08-00-00488 (Beilstein Handbook Reference)
Histamine 1H-Imidazole-5-ethanamine; Histamine; 51-45-6; 2-(1H-imidazol-5-yl)ethanamine; 1H-Imidazole-4-ethanamine; 2-(4-Imidazolyl)ethylamine; Ergamine; Ergotidine; Eramin; 5-Imidazoleethylamine; Theramine; 2-Imidazol-4-ylethylamine; Free histamine; 2-(1H-Imidazol-4-yl)ethanamine; beta-Aminoethylimidazole; Imidazole-4-ethylamine; beta-Aminoethylglyoxaline; Histamine Base; 4-(2-Aminoethyl)-1H-imidazole; Istamina; 2-(1H-imidazol-4-yl)ethan-1-amine; 4-Imidazoleethylamine; 1H-Imidazole-5-ethanamine; 65592-96-3; beta-Imidazolyl-4-ethylamine; Histamine [USAN]; Istamina [Italian]; Ethylamine, 2-imidazol-4-yl-; Imidazole, 4-(2-aminoethyl)-; Histamine, Free Base; L-histamine; 2-(3H-Imidazol-4-yl)-ethylamine; [3H]histamine; beta-aminothethylglyoxaline; NSC 33792; peremin; CCRIS 6535; CHEBI:18295; HSDB 3338; UNII-820484N8I3; CHEMBL90; EINECS 200-100-6; 2-imidazol-5-ylethylamine; 4-(2-Aminoethyl)imidazole; Histamin; MLS000069447; .beta.-Imidazolyl-4-ethylamine; 2-(1H-Imidazol-4-yl)ethylamine; NTYJJOPFIAHURM-UHFFFAOYSA-N; Histamine, 97%; MFCD00005210; NSC-33792; 2-(1H-imidazol-5-yl)ethan-1-amine; NCGC00015513-04; SMR000059091; 820484N8I3; DSSTox_CID_3125; DSSTox_RID_76884; DSSTox_GSID_23125; 2-(3H-imidazol-4-yl)ethanamine; CAS-51-45-6; Histaminum (TN); Histamine (DCF); Histamium; 3h-histamine; imido-; L-Histamin base; Racemic histamine; 1avn; 1qft; ALBB-005968; Spectrum_000845; Opera_ID_1772; Spectrum2_000665; Spectrum3_000452; Spectrum4_000960; Spectrum5_000796; Lopac-H-7250; b-Imidazolyl-4-ethylamine; .beta.-Aminoethylimidazole; bmse000744; .beta.-Aminoethylglyoxaline; Histamine, >=97.0%; SCHEMBL2279; 2-(4-Imidazolyl)ethanamine; 2-imidazol-4-yl-Ethylamine; Lopac0_000595; WLN: T5M CNJ D2Z; BSPBio_001117; BSPBio_002124; KBioGR_000457; KBioGR_001580; KBioSS_000457; KBioSS_001325; DivK1c_000308; Histamine, analytical standard; SPBio_000729; (1H-imidazol-4-yl)ethylamine; BDBM7966; GTPL1204; GTPL1247; DTXSID4023125; BCBcMAP01_000250; CTK1G9684; CTK5C2901; KBio1_000308; KBio2_000457; KBio2_001325; KBio2_003025; KBio2_003893; KBio2_005593; KBio2_006461; KBio3_000853; KBio3_000854; KBio3_001344; KS-00000XSS; F411C768-A159-4FC0-A195-291A08BB03AA; 2-(1H-Imidazol-5-yl)ethylamine; 2-(3H-imidazol-4-yl)ethylamine; NINDS_000308; Bio1_000487; Bio1_000976; Bio1_001465; Bio2_000389; Bio2_000869; HMS1362G19; HMS1792G19; HMS1990G19; HMS3403G19; HMS3743G03; ZINC388081; 2-(1H-Imidazol-4-yl)-ethylamine; HY-B1204; NSC33792; Tox21_110166; [2-(1H-imidazol-4-yl)ethyl]amine; 2-(1H-Imidazol-4-yl)ethanamine #; ANW-50461; BBL004932; BDBM50121205; Histamine Dihydrochloride (Salt/Mix); s3968; SBB012708; STK346752; AKOS000274386; AKOS009158347; Histamine, base, >=97.0% (NT); Tox21_110166_1; CCG-204684; CS-4697; DB05381; FS-5386; MCULE-4970362785; RTR-018324; SDCCGMLS-0066601.P001; SDCCGSBI-0050577.P005; IDI1_000308; IDI1_002144; SMP1_000151; NCGC00015513-01; NCGC00015513-02; NCGC00015513-03; NCGC00015513-05; NCGC00015513-06; NCGC00015513-07; NCGC00015513-08; NCGC00015513-09; NCGC00015513-10; NCGC00015513-11; NCGC00093371-02; NCGC00093371-03; NCGC00093371-04; NCGC00093371-05; AC-13185; BP-11484; BR-47510; LS-75835; ST073926; SY041787; SBI-0050577.P004; TR-018324; AM20100377; BB 0241907; FT-0627839; Y9749; Histamine, Vetec(TM) reagent grade, >=97%; 2631-EP2268638A1; 2631-EP2269989A1; 2631-EP2269990A1; 2631-EP2270002A1; 2631-EP2275420A1; 2631-EP2277565A2; 2631-EP2277566A2; 2631-EP2277567A1; 2631-EP2277568A2; 2631-EP2277569A2; 2631-EP2277570A2; 2631-EP2277848A1; 2631-EP2280001A1; 2631-EP2281563A1; 2631-EP2286811A1; 2631-EP2287165A2; 2631-EP2287166A2; 2631-EP2292280A1; 2631-EP2292619A1; 2631-EP2292620A2; 2631-EP2295409A1; 2631-EP2295423A1; 2631-EP2298734A2; 2631-EP2298767A1; 2631-EP2298772A1; 2631-EP2298776A1; 2631-EP2300422A1; 2631-EP2301937A1; 2631-EP2305260A1; 2631-EP2305640A2; 2631-EP2305648A1; 2631-EP2305652A2; 2631-EP2305668A1; 2631-EP2305677A1; 2631-EP2308873A1; 2631-EP2311801A1; 2631-EP2311802A1; 2631-EP2311803A1; 2631-EP2311831A1; 2631-EP2314574A1; 2631-EP2314587A1; 2631-EP2316459A1; 2631-EP2316824A1; 2631-EP2316831A1; 2631-EP2371814A1; C-5322; C00388; D08040; Q61233; AB00053481_20; AB00053481_21; 056H928; 163355-EP2270002A1; 163355-EP2284166A1; 714I940; L000292; J-505349; Histamine, EuropePharmacopoeia (EP) Reference Standard; 2-imidazol-4-ylethylamine--orthophosphoric acid (1:2); F2173-0575; Histamine; beta-Aminoethylglyoxaline
Histrelin 6-[1-(Phenylmethyl)-D-1-9-luteinizing hormone-releasing factor (swine); Histrelin; BRN 4290557
Homatropine methylbromide (3-Endo)-3-[(2-hydroxy-2-phenylacetyl)oxy]-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide (1:1); Homatropine methylbromide; Arkitropin
Homocysteine L-Homocysteine; L-Homocysteine; homocysteine; 6027-13-0; (2S)-2-amino-4-sulfanylbutanoic acid; UNII-0LVT1QZ0BA; (s)-2-amino-4-mercaptobutanoic acid; CHEBI:17588; L-2-Amino-4-mercaptobutyric acid; 0LVT1QZ0BA; CHEMBL469662; H-2800; 2-AMINO-4-MERCAPTO-BUTYRIC ACID; Butyric acid, 2-amino-4-mercapto-; Hcy; HCS; Homocysteine (VAN); MFCD00151320; 454-28-4; EINECS 227-891-0; NSC 43117; NSC 118376; 2-Amino-4-mercaptobutyric acid (VAN); Butanoic acid, 2-amino-4-mercapto- (VAN); Butanoic acid, 2-amino-4-mercapto-, (S)-; Epitope ID:143650; SCHEMBL35837; GTPL5198; DTXSID3041039; CTK2F4183; FFFHZYDWPBMWHY-VKHMYHEASA-N; ZINC895077; (S)-2-Amino-4-mercaptobutyric acid; ACM454284; BDBM50242405; FCH839844; KM0387; L-Homocysteine, >=98.0% (NT); AKOS006272166; CS-W011063; DB04422; FS-6405; KS-0000000A; LS-75889; AB1007104; Butyric acid, 2-amino-4-mercapto- (8CI); FT-0082585; FT-0627845; C00155; Butyric acid, 2-amino-4-mercapto-, L- (8CI); Q26992833; UNII-S7IJP4A89K component FFFHZYDWPBMWHY-VKHMYHEASA-N; S-Methyl-L-homocysteine; L-2-Amino-4-mercapto-butyric acid; (S)-2-Amino-4-mercapto-butanoic acid; Homocysteine; 2-Amino-4-mercaptobutyric acid
Homogentisic acid 2,5-Dihydroxybenzeneacetic acid; Homogentisic acid; 4-10-00-01506 (Beilstein Handbook Reference)
Honokiol 3',5-Di-2-propen-1-yl[1,1'-Biphenyl]-2,4'-diol; Honokiol; 35354-74-6; 5,3'-Diallyl-2,4'-dihydroxybiphenyl; NSC 293100; 3,5'-Diallyl-4,2'-dihydroxybiphenyl; Honokiol,(S); UNII-11513CCO0N; 3',5-Diallylbiphenyl-2,4'-diol; C18H18O2; CPD000387107; CHEMBL16901; CHEBI:5759; 3',5-diallyl-[1,1'-biphenyl]-2,4'-diol; 4-allyl-2-(3-allyl-4-hydroxy-phenyl)phenol; 11513CCO0N; 3',5-diallyl-2,4'-biphenyldiol; [1,1'-Biphenyl]-2,4'-diol, 3',5-di-2-propenyl-; AK-25837; Q-100425; SMR000387107; 3',5-di(prop-2-en-1-yl)biphenyl-2,4'-diol; Honokiol, HO; 5,3′ 5,3′ -Diallyl-2,4′ -dihydroxydiphenyl; Honokiol, analytical standard; cid_72303; MLS000759481; MLS001048916; MLS001423980; MLS006011755; SCHEMBL133034; REGID_for_CID_72303; ZINC1536; CTK5J3931; KS-00000NQF; DTXSID30188845; 3',1'-biphenyl)-2,4'-diol; FVYXIJYOAGAUQK-UHFFFAOYSA-N; HMS2051C12; HMS2271J07; HMS3393C12; HMS3656G03; BCP28282; HY-N0003; 3',5'-Diallyl-2,4'-biphenyldiol; 5,3'-Diallyl-biphenyl-2,4'-diol; AC-486; ANW-56605; BBL027819; BDBM50157304; BN0719; MFCD00016674; NSC293100; s2310; STK801954; 3'',5-diallylbiphenyl-2,4''-diol; Honokiol, >=98% (HPLC), powder; 3,5'-diallyl-2',4-dihydroxybiphenyl; AKOS005622639; 3',5-Diallyl-2,4'-dihydroxybiphenyl; ACN-035410; API0002927; AT-5464; CCG-100864; CS-1696; MCULE-5001549020; NC00114; NSC-293100; RTR-014635; VZ32385; 5,3''-Diallyl-biphenyl-2,4''-diol; SMP2_000040; NCGC00163567-01; NCGC00163567-02; NCGC00163567-03; 4CN-0876; AS-15333; O900; SAM001246690; SC-17371; AB0016711; AX8008971; LS-174528; TR-014635; 5,3''''-Diallyl-biphenyl-2,4''''-diol; FT-0601638; N1672; ST24044036; SW197494-3; A10453; C10630; J10347; W-2613; 354H746; SR-01000758208; Q5896650; SR-01000758208-5; {1,1'-Biphenyl]-2,4'-diol, 3,5-di-2-propenyl-; 3'',5-di-2-propenyl-1,1''-biphenyl-2,4''-diol; BRD-K98493452-001-01-6; 3',5-Di-2-propen-1-yl[1,1'-biphenyl]-2,4'-diol; Honokiol, European Pharmacopoeia (EP) Reference Standard; [1,1'-Biphenyl]-2,4'-diol, 3',5-di-2-propen-1-yl-; InChI=1/C18H18O2/c1-3-5-13-7-9-18(20)16(11-13)14-8-10-17(19)15(12-14)6-4-2/h3-4,7-12,19-20H,1-2,5-6H; Honokiol; Honokiol
Hydrochlorothiazide 6-Chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; Hydrochlorothiazide; Aldactazide 25/25
Hydrocortisone acetate (11beta)-21-Acetyloxy)-11,17-dihydroxypregn-4-ene-3,20-dione; Hydrocortisone acetate [USP:BAN:JAN]; Abbocort
Hydroxyproline trans-4-Hydroxy-L-proline; 51-35-4; trans-4-Hydroxy-L-proline; L-Hydroxyproline; hydroxyproline; trans-4-Hydroxyproline; (2S,4R)-4-Hydroxypyrrolidine-2-carboxylic acid; L-4-hydroxyproline; H-Hyp-OH; hydroxy-L-proline; Hypro; 4-hydroxyproline; trans-L-Hydroxyproline; (4R)-4-hydroxy-L-proline; 4-Hydroxy-L-proline; L-Proline, 4-hydroxy-, (4R)-; 4-Hydroxy-2-pyrrolidinecarboxylic acid; trans-Hydroxyproline; Hydroxyproline (VAN); Ls-Hydroxyproline; UNII-RMB44WO89X; Proline, 4-hydroxy-, L-; delta-Hydroxyproline; 4-L-Hydroxyproline; Proline, 4-hydroxy- (VAN); L-Proline, 4-hydroxy-; Proline, 4-hydroxy-; RMB44WO89X; CHEMBL352418; CHEBI:18095; (2S,4R)-trans-4-hydroxyproline; Trans-4-Hydroxy-L-Proline, 99+%; Z-TRANS-4-HYDROXY-L-PROLINE; (2S,4R)-(-)-4-Hydroxy-2-Pyrrolidinecarboxylic Acid; L-Proline, 4-hydroxy-, trans-; L-Proline, 4-hydroxy-, trans- (9CI); (2S,4R)-4-hydroxy-2-pyrrolidinecarboxylic acid; (2S,4R)-4-hydroxyproline; EINECS 200-091-9; MFCD00064320; NSC 46704; SMR000857104; trans-4-hydroxy-proline; hydroxiproline; oxyproline; hydroxy-proline; trans-4-hydroxy-D,L-proline; Pyrrolidin-4-ol-2-carboxylic acid; Hyp; L-Hydroxyproline; h-l-hyp-oh; H-trans-Hyp-OH; hydroxyproline, l-; Hydroxyproline,(l); L-Proline, trans-; (4r)-hydroxyproline; 4(R)-hydroxyproline; (2s,4r)-(-)-4-hydroxypyrrolidine-2-carboxylic acid; .delta.-Hydroxyproline; L-Hydroxyproline,(S); L-4-transhydroxyproline; L-threo-4-hydroxyproline; trans-4-hydroxyL-proline; Trans4-hydroxy-L-proline; bmse000123; bmse000966; L-trans-4-hydroxy-proline; trans-4-hydroxy(L)proline; trans-4-hydroxyl-l-proline; SCHEMBL21185; KSC269I9J; MLS001332463; MLS001332464; trans-4-hydroxy-(L)-proline; (2S, 4R)-4-hydroxyproline; GTPL4704; (2s,4r)-4-hydroxy-l-proline; (2S, 4R)-4-hydroxy-proline; CTK1G9494; DTXSID10883225; PMMYEEVYMWASQN-DMTCNVIQSA-N; ZINC901791; ACT08225; KS-00000O2S; NSC46704; ANW-31245; BDBM50357233; CH-388; NSC-46704; s5820; SBB004222; trans-4-Hydroxy-L-proline, >=99%; AKOS007930607; AB02585; AC-2249; AM81829; CS-W008928; DB08847; LS30143; MCULE-5389747201; PS-5807; KS-0000050M; (2S,4R)-2-carboxy-4-hydroxypyrrolidine; 54733-36-7; BP-10638; BR-26056; HY-40135; NCI60_004102; AB0063025; AB1001753; TX-018154; FT-0634378; FT-0639142; C01157; H-7290; M-5819; M03214; trans-4-Hydroxy-L-proline, analytical standard; 33779-EP2272822A1; 33779-EP2272972A1; 33779-EP2272973A1; 33779-EP2277867A2; 33779-EP2277872A1; 33779-EP2277877A1; 33779-EP2277898A2; 33779-EP2280003A2; 33779-EP2295055A2; 33779-EP2311453A1; (2S, 4R)-4-hydroxy-2-pyrrolidinecarboxylic acid; (2S,4R)-4-hydroxy-pyrrolidine-2-carboxylic acid; 064H320; 4-(R)-hydroxy-pyrrolidine-2-(S)-carboxylic acid; (2S, 4R)-4-hydroxy-2-pyrrolidine-carboxylic acid; J-525022; Q27089020; trans-4-Hydroxy-L-proline, BioXtra, >=99.0% (NT); F8889-8652; Z1259273356; F05487BD-FA1D-4C80-83AD-3A91E2078031; trans-4-Hydroxy-L-proline, microbial, cell culture tested; trans-4-Hydroxy-L-proline, Vetec(TM) reagent grade, 99%; UNII-9J17BCS69U component PMMYEEVYMWASQN-DMTCNVIQSA-N; UNII-SZB83O1W42 component PMMYEEVYMWASQN-DMTCNVIQSA-N; trans-4-Hydroxy-L-proline, BioReagent, suitable for cell culture, >=98.5%; Hydroxyproline, Pharmaceutical Secondary Standard; Certified Reference Material; Hydroxyproline; EINECS 200-091-9
Hydroxyurea hydroxyurea; Hydroxycarbamide; 127-07-1; N-Hydroxyurea; 1-HYDROXYUREA; Hydrea; Oxyurea; Carbamoyl oxime; Biosupressin; Hydroxycarbamine; Urea, hydroxy-; Onco-carbide; Carbamohydroxamic acid; Carbamohydroximic acid; Carbamyl hydroxamate; Hydura; Litalir; Hydurea; N-Carbamoylhydroxylamine; Droxia; Hidrix; Hydroxicarbamidum; Siklos; Hydroxylurea; Hydreia; Litaler; Idrossicarbamide [DCIT]; Hidroxicarbamida; Hydroxyharnstoff; Hydroxycarbamidum; Carbamohydroxyamic acid; N-Hydroxymocovina; Hydroxylamine, N-carbamoyl-; Hydroxyharnstoff [German]; N-Hydroxymocovina [Czech]; SQ 1089; NCI-C04831; Hydroxylamine, N-(aminocarbonyl)-; SK 22591; Hydroxycarbamidum [INN-Latin]; Hidroxicarbamida [INN-Spanish]; urea, N-hydroxy-; HU; CCRIS 958; HYDROXY-UREA; NSC 32065; UNII-X6Q56QN5QC; NSC32065; AI3-51139; HSDB 6887; Hydroxyurea (Cytodrox); EINECS 204-821-7; MFCD00007943; CHEMBL467; SQ-1089; BRN 1741548; X6Q56QN5QC; CHEBI:44423; VSNHCAURESNICA-UHFFFAOYSA-N; Hydroxyurea, 98%; NSC-32065; NCGC00015520-03; Hydroxycarbamid; Oncocarbide; Idrossicarbamide; DSSTox_CID_5438; DSSTox_RID_77787; DSSTox_GSID_25438; NHY; Hydroxyurea (D4); N-HYDROXY UREA; Mylocel; carbamide oxide; Hydroxyurea [USAN:BAN]; CAS-127-07-1; SMR000059149; Hydroxyurea (USP); Droxia (TM); Droxia (TN); Hydrea (TM); hydroxyaminomethanamide; SR-01000075919; DRG-0253; HYDREA (TN); Hydroxyurea [USAN:USP]; Hydroxycarbamide (JAN/INN); hydroxyl urea; hydroxy urea; Xromi; 1-oxidanylurea; S-phase/G-1 interface inhibitor; aminohydroxamic acid; carbamic acid oxime; Hydroxy Urea-15N; Carbomohydroxamic acid; Spectrum_000909; Hydroxycarbamide [INN]; WLN: ZVMQ; Hydrea (Bristol Meyers); Spectrum2_000064; Spectrum3_000462; Spectrum4_000012; Spectrum5_000836; Lopac-H-8627; MolMap_000029; H 8627; NCIMech_000139; Hydroxyurea, 98%, powder; ACMC-1C22W; Lopac0_000596; BSPBio_002164; KBioGR_000383; KBioSS_001389; 4-03-00-00170 (Beilstein Handbook Reference); hydroxycarbamide (hydroxyurea); KSC490O3R; MLS001332381; MLS001332382; MLS002153389; DivK1c_000556; N-(Aminocarbonyl)hydroxylamine; SPECTRUM1500344; SPBio_000247; GTPL6822; DTXSID6025438; tetratogen: inhibits ribonucleoside diphosphate reductase; CTK3J0738; HMS501L18; KBio1_000556; KBio2_001389; KBio2_003957; KBio2_006525; KBio3_001384; NINDS_000556; Bio1_000451; Bio1_000940; Bio1_001429; HMS1920F09; HMS2091L17; HMS2234I03; HMS3261H14; HMS3373G18; HMS3655K20; NCI C04831; Pharmakon1600-01500344; ACT02611; ALBB-028465; EBD12517; HY-B0313; STR02555; ZINC8034120; Tox21_110168; Tox21_300319; Tox21_500596; ANW-18958; BBL009928; BDBM50017811; CCG-35236; LS-709; NSC757072; s1896; STL145898; AKOS005716276; AKOS006222547; Tox21_110168_1; ZINC100019199; CS-2353; DB01005; LP00596; MCULE-9465284053; NSC-757072; RTR-003905; SDCCGSBI-0050578.P006; IDI1_000556; KS-0000020X; TRA-0204880; NCGC00015520-01; NCGC00015520-02; NCGC00015520-04; NCGC00015520-05; NCGC00015520-06; NCGC00015520-07; NCGC00015520-08; NCGC00015520-09; NCGC00015520-10; NCGC00015520-11; NCGC00093974-01; NCGC00093974-02; NCGC00093974-03; NCGC00093974-04; NCGC00093974-05; NCGC00254007-01; NCGC00261281-01; AC-22674; AK128930; NCI60_002773; SC-17803; SBI-0050578.P004; AB0013265; AB1009531; DB-041849; ST2415349; TR-003905; EU-0100596; FT-0083575; FT-0627160; SW218071-2; C07044; D00341; Hydroxyurea, Vetec(TM) reagent grade, >=98%; AB00052018-09; AB00052018-10; AB00052018_11; AB00052018_12; 127H071; A805636; Q212272; J-504798; SR-01000075919-1; SR-01000075919-3; SR-01000075919-8; E0723DBA-5AF3-49D1-B5F6-59420AB87AC9; F8880-0905; Z1522566612; Hydroxycarbamide, European Pharmacopoeia (EP) Reference Standard; Hydroxyurea, United States Pharmacopeia (USP) Reference Standard; 8029-68-3; 4-03-00-00170 (Beilstein Handbook Reference)
Hymecromone 7-Hydroxy-4-methyl-2H-1-benzopyran-2-one; Hymecromone; 5-18-01-00439 (Beilstein Handbook Reference)
Hyperforin (1R,5S,6R,7S)-4-Hydroxy-6-methyl-1,3,7-tris(3-methyl-2-buten-1-yl)-5-(2-methyl-1-oxopropyl)-6-(4-methyl-3-penten-1-yl)bicyclo[3.3.1]non-3-ene-2,9-dione; Hyperforin; HSDB 7646
Hypericin 1,3,4,6,8,13-Hexahydroxy-10,11-dimethylphenanthro[1,10,9,8-opqra]perylene-7,14-dione; hypericin; 548-04-9; Hypericum red; hipericihypericine; Hyperizin; Cyclosan; 1,3,4,6,8,13-Hexahydroxy-10,11-dimethylphenanthro[1,10,9,8-opqra]perylene-7,14-dione; Cyclo-Werol; Hypericum Extract; VIMRxyn; UNII-7V2F1075HD; C30H16O8; EINECS 208-941-0; NSC407313; Hypericin & Visible light; NSC 407313; NSC 622946; (component of) Hypericum spp (st. John's wort); 7V2F1075HD; MFCD00016683; NSC622946; Cyclo werrol; 4,5,7,4',5',7'-Hexahydroxy-2,2'-dimethylnaphthodianthrone; 4,5,7,4',5',7'-Hexahydroxy-2,2'-dimethyl-mesonapthtodianthron; 1,3,4,6,8,13-Hexahydroxy-10,11-dimethylphenanthro(1,10,9,8-opqra)perylene-7,14-dione; hexahydroxy(dimethyl)[?]dione; Q-100618; 1:6:8:10:11:13-hexahydroxy-3:4-dimethyl-meso-naphthodianthrene-7:14-dione; Phenanthro[1,10,9,8-opqra]perylene-7,14-dione, 1,3,4,6,8,13-hexahydroxy-10,11-dimethyl-; Mycoporphyrin; Vimr; Cyclo-werrol; CCRIS 8166; Hypericin?; BiomolKI_000032; BiomolKI2_000040; SCHEMBL3182; BIDD:PXR0084; BMK1-D8; SCHEMBL10262695; BIH1002; DTXSID40203270; BTXNYTINYBABQR-UHFFFAOYSA-N; ZX-AFC000188; Hypericin from Hypericum perforatum; HY-N0453; ZINC3780340; BDBM50060874; CCG-36081; CH-268; GE3282; HSCI1_000202; LMPK13040001; AKOS015895658; AC-6048; CS-5687; EBD2048972; MCULE-7319800130; NSC-622946; NCGC00162454-01; NCGC00163378-01; NCGC00163378-02; 4CN-1297; AS-74733; CC-29451; NCI60_003879; NCI60_006799; SC-18495; NCGC00163378-03!; LS-175574; FT-0627169; N2739; C07606; 33919-EP2275420A1; 33919-EP2295055A2; 33919-EP2295416A2; 33919-EP2298748A2; 33919-EP2298764A1; 33919-EP2298765A1; 33919-EP2305642A2; 33919-EP2311453A1; 548H049; C-22963; SR-05000002344; Hypericin from Hypericum perforatum, ~95% (HPLC); Hypericin, primary pharmaceutical reference standard; SR-05000002344-2; BRD-K29673530-001-03-9; 4,4',5,5',7,7'-Hexahydroxy-2,2'-dimethylnaphthodianthrone; 3,4,6,7,13,14-Hexahydroxy-10,11-dimethylphenanthro[1,10,9,8-opqra]perylene-1,8-dione; 3,4,7,8,13,14-Hexahydroxy-10,11-dimethylphenanthro[1,10,9,8-opqra]perylene-1,6-dione; 1,3,4,6,8,13-Hexahydroxy-10,11-dimethylphenanthro[1,10,9,8-opqra]perylene-7,14-dione, 9CI; 1,4,6,8,13-Hexahydroxy-10,11-dimethylphenanthro [1,10,9,8-opqra]perylene-7,14-dione P-conformer; 5,7,11,18,22,24-HEXAHYDROXY-13,16-DIMETHYLOCTACYCLO[13.11.1.1(2),(1)?.0(3),?.0?,(2)?.0(1)?,(2)?.0(2)(1),(2)?.0(1)?,(2)?]OCTACOSA-1,3,5,7,10,12,14(28),15(27),16,18,21,23,25-TRIDECAENE-9,20-DIONE; InChI=1/C30H16O8/c1-7-3-9(31)19-23-15(7)16-8(2)4-10(32)20-24(16)28-26-18(12(34)6-14(36)22(26)30(20)38)17-11(33)5-13(35)21(29(19)37)25(17)27(23)28/h3-6,31-36H,1-2H; Phenanthro[1,10,9,8-opqra]perylene-7,14-dione,1,3,4,6,8,13-hexahydroxy-10,11-dimethyl-, stereoisomer; Phenanthro[1,9,8-opqra]perylene-7,14-dione,1,3,4,6,8,13-hexahydroxy-10,11-dimethyl-, stereoisomer; Hypericin; EINECS 208-941-0
Hypoxanthine 1,7-Dihydro-6H-purin-6-one; hypoxanthine; 68-94-0; 6-Hydroxypurine; 9H-Purin-6-ol; Sarkin; 6-Oxopurine; Sarcine; Sarkine; 7H-Purin-6-ol; Purin-6(1H)-one; Purin-6-ol; Hypoxanthine enol; 6(1H)-Purinone; 1,7-Dihydro-6H-purin-6-one; 3H-Purin-6-ol; 9H-Purin-6(1H)-one; Purin-6(3H)-one; 6-Hydroxy-1H-purine; 6H-Purin-6-one, 1,7-dihydro-; Purine-6-ol; 1H-Purin-6(9H)-one; 9H-Purin-6-ol (VAN); 1,9-dihydro-6H-purin-6-one; 6H-Purin-6-one, 1,9-dihydro-; MFCD00005725; NSC 14665; 1H-Purin-6-ol (9CI); 3H-Purin-6-ol (9CI); UNII-2TN51YD919; 1h-purin-6-ol; 6,7-dihydro-3H-purin-6-one; 146469-94-5; 1,7-Dihydro-6H-purine-6-one; CHEBI:17368; AI3-52242; EINECS 200-697-3; 1,9-dihydropurin-6-one; 95121-06-5; HX; CHEMBL1427; Hypoxanthine (VAN) (8CI); 146469-95-6; 51953-04-9; FDGQSTZJBFJUBT-UHFFFAOYSA-N; 2TN51YD919; 146445-70-7; NCGC00095622-01; AK-96690; Hypoxanthine, 99.5%; DSSTox_CID_25983; DSSTox_RID_81271; DSSTox_GSID_45983; AG-670/31547063; CAS-68-94-0; 51953-23-2; purin-6(1H)-on; 9H-Purin-6-ol (9CI); 3h-hypoxanthine; 6-hydroxypurin; 1vfn; 3nrz; Hypoxanthine,(S); Hypoxanthine (VAN); 1H,7H-Hypoxanthine; NSC 129419; PubChem9283; 1246820-04-1; 244769-71-9; 4-Hydroxy-1H-purine; Spectrum_001417; 1a9q; 7H-Purin-6-ol #; SpecPlus_000461; Spectrum2_001907; Spectrum3_001352; Spectrum4_001742; Spectrum5_000564; 3H-purin-6(7H)-one; ACMC-1AY8Z; ACMC-209o5e; bmse000094; Epitope ID:167471; 1,9-Dihydro-purin-6-one; Hypoxanthine, >=99.0%; ACMC-1C9T0; SCHEMBL25381; BSPBio_003163; KBioGR_002184; KBioSS_001897; SPECTRUM310023; KSC353S0F; DivK1c_006557; SPBio_001874; GTPL4555; SCHEMBL1867923; DTXSID8045983; SCHEMBL17276814; BDBM82018; CTK0H0419; CTK0H0424; CTK1E4768; CTK1G8777; CTK2F3902; CTK3I5985; FDGQSTZJBFJUBT-UHFFFAOYSA-; KBio1_001501; KBio2_001897; KBio2_004465; KBio2_007033; KBio3_002383; CAS_790; NSC_790; BCP22929; HY-N0091; NSC14665; Tox21_111511; ANW-35568; CCG-38478; CH0066; EBD130553; NSC-14665; PDSP1_000299; PDSP2_000297; s2424; SBB004203; STK804424; ZINC18153302; AKOS000267572; AKOS005221762; AKOS009159101; AKOS015888571; AKOS022168213; Tox21_111511_1; 6-Hydroxypurine; Purin-6-ol; Sarcine; DB04076; MCULE-8326019285; PS-3167; SDCCGMLS-0065594.P001; SDCCGMLS-0065594.P002; NCGC00095622-04; AC-10518; CC-29453; SC-06274; SY012477; AB0008347; DB-029904; LS-127207; CS-0007792; FT-0627170; ST50160486; SW219908-1; 1,7-Dihydro-6H-purin-6-one (Hypoxanthine); Discontinued. See H998503 or H998504"; EN300-37579; Hypoxanthine, Vetec(TM) reagent grade, 98%; Hypoxsanthine (1,7-Dihydro-6H-purin-6-one); 2899-EP2269996A1; 2899-EP2270008A1; 2899-EP2270505A1; 2899-EP2292617A1; 2899-EP2292630A1; 2899-EP2295503A1; 2899-EP2302382A2; 2899-EP2302383A2; 2899-EP2316974A1; 68H940; C00262; Z-4186; 30233-EP2277880A1; 30233-EP2284165A1; 30233-EP2287167A1; 30233-EP2292604A2; 30233-EP2292610A1; 30233-EP2292615A1; 30233-EP2295433A2; 30233-EP2305825A1; 30233-EP2311464A1; AB00674258-01; Q410305; SR-05000002375; SR-05000002375-1; W-104648; F1386-0269; Hypoxanthine, powder, BioReagent, suitable for cell culture; 8C229956-6BE8-4F8D-91B7-0AD1EC294077; Didanosine impurity A,, European Pharmacopoeia (EP) Reference Standard; Didanosine Related Compound A, United States Pharmacopeia (USP) Reference Standard; InChI=1/C5H4N4O/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10); Hypoxanthine, PharmaGrade, Manufactured under appropriate controls for use as a raw material in pharma or biopharmaceutical production.; Hypoxanthine; AI3-52242
Ibuprofen alpha-Methyl-4-(2-methylpropyl)benzeneacetic acid; Ibuprofen; U-18,573
Ibuprofen sodium alpha-Methyl-4-(2-methylpropyl)benzeneacetic acid, Sodium salt (1:1); Ibuprofen sodium anhydrous; EINECS 250-477-6
Idazoxan 2-(2,3-Dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole; IDAZOXAN; 79944-58-4; Idazoxane; Idazoxano; Idazoxanum; Idazoxane [French]; Idazoxanum [Latin]; 2-(2,3-Dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole; Idazoxano [Spanish]; CHEMBL10316; RX-781094; CHEBI:5862; HPMRFMKYPGXPEP-UHFFFAOYSA-N; NCGC00015560-06; DSSTox_CID_25161; DSSTox_RID_80711; (+-)-2-(1,4-Benzodioxan-2-yl)-2-imidazoline; DSSTox_GSID_45161; 4,5-dihydro-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-1H-imidazole; 1H-Imidazole, 4,5-dihydro-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-; CAS-79944-58-4; Idazoxan [BAN:INN]; Idazoxan [INN:BAN]; idasoxan; 2-(2,3-dihydro-1,4-benzodioxin-3-yl)-4,5-dihydro-1H-imidazole; Prestwick0_000926; Prestwick1_000926; Prestwick2_000926; Prestwick3_000926; Lopac0_000652; US8633208, Idazoxan; BSPBio_000832; SCHEMBL114731; SPBio_003011; BPBio1_000916; DTXSID6045161; HMS2089E14; Tox21 110173; Tox21_110173; BDBM50019848; 2-(1,4-benzodioxan-2-yl)imidazoline; AKOS015915004; Tox21_110173_1; API0007263; CCG-204739; DB12551; SDCCGSBI-0050632.P003; NCGC00015560-04; NCGC00015560-05; NCGC00015560-08; NCGC00015560-09; NCGC00015560-10; NCGC00015560-12; NCGC00024794-03; NCGC00024794-04; LS-78447; SBI-0050632.P002; AB00514632; FT-0655996; C10968; AB00489883-09; AB00489883_10; A839791; L000808; Q5987770; BRD-A18696154-003-03-6; BRD-A18696154-003-14-3; Idazoxan
Ifenprodil alpha-(4-Hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidineethanol; Ifenprodil; 4-Benzyl-alpha-(p-hydroxyphenyl)-beta-methyl-1-piperidineethanol
Ifosfamide N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; Ifosfamide; A 4942
Imidazole imidazole; 1H-Imidazole; 288-32-4; Glyoxaline; Imidazol; Iminazole; Miazole; 1,3-Diazole; Glyoxalin; Imutex; 1,3-Diaza-2,4-cyclopentadiene; Pyrro(b)monazole; USAF EK-4733; Pyrro[b]monazole; Formamidine, N,N'-vinylene-; Glioksal [Polish]; Glioksal; Methanimidamide, N,N'-1,2-ethenediyl-; IMD; CCRIS 3345; AI3-24703; UNII-7GBN705NH1; NSC 60522; BRN 0103853; N,N'-vinyleneformamidine; EINECS 206-019-2; NSC 51860; CHEMBL540; 7GBN705NH1; DTXSID2029616; CHEBI:16069; RAXXELZNTBOGNW-UHFFFAOYSA-N; N,N'-1,2-ethenediylmethanimidamide; Imidazole, 99%; MFCD00005183; Imidazole, ACS reagent; DSSTox_CID_9616; DSSTox_RID_78788; DSSTox_GSID_29616; Imidazole, 99+%, crystalline; 1H-imidazol; CAS-288-32-4; Imidazole (8CI); NSC51860; Imidazole, puriss. p.a., >=99.5% (GC); Immidazole; imidazole-; 1-H-imidazole; {Pyrro[b]monazole}; 1,4-cyclopentadiene; Imidazole; Glyoxaline; ACMC-1CPAG; 1H-Imidazole (9CI); Formamidine,N'-vinylene-; bmse000096; bmse000790; WLN: T5M CNJ; EC 206-019-2; NCIStruc1_001975; NCIStruc2_000693; Imidazole, LR, >=99%; 5-23-04-00191 (Beilstein Handbook Reference); KSC203M9T; MLS001055465; BDBM7882; CTK1A3699; HSDB 8449; 1,3-Diaza-2,4-cyclopentadiene-; Imidazole, ReagentPlus(R), 99%; ZINC901039; Imidazole, for synthesis, 99.5%; BCP26547; HY-D0837; KS-000002NA; NSC60522; Methanimidamide,N'-1,2-ethenediyl-; Tox21_201504; Tox21_303345; ANW-26483; BBL009685; NSC-60522; s6006; SBB040815; STK362967; AKOS000120177; AM82000; CS-5135; DB03366; MCULE-1410806694; RTR-036369; Imidazole, BioUltra, >=99.5% (GC); NCGC00090984-01; NCGC00090984-02; NCGC00257344-01; NCGC00259055-01; 2,4-Diazonia-2,4-cyclopentadiene-1-ide; AK-76381; BP-11451; Him; LS-77964; SC-18719; SMR000057825; ST097249; 1,3-Diaza-2,4-cyclopentadiene; Glyoxaline; Imidazole, SAJ special grade, >=99.0%; Imidazole, Vetec(TM) reagent grade, 98%; AB1002136; DB-002018; ST2408897; TR-036369; FT-0627179; I0001; I0014; I0288; I0290; Imidazole, >=99% (titration), crystalline; Imidazole, ACS reagent, >=99% (titration); 2519-EP0930075A1; 2519-EP1441224A2; 2519-EP2269977A2; 2519-EP2269978A2; 2519-EP2269985A2; 2519-EP2269990A1; 2519-EP2269991A2; 2519-EP2269992A1; 2519-EP2270002A1; 2519-EP2270006A1; 2519-EP2270008A1; 2519-EP2270010A1; 2519-EP2270011A1; 2519-EP2270014A1; 2519-EP2270015A1; 2519-EP2270113A1; 2519-EP2270505A1; 2519-EP2272509A1; 2519-EP2272510A1; 2519-EP2272516A2; 2519-EP2272517A1; 2519-EP2272537A2; 2519-EP2272813A2; 2519-EP2272817A1; 2519-EP2272825A2; 2519-EP2272827A1; 2519-EP2272828A1; 2519-EP2272832A1; 2519-EP2272838A1; 2519-EP2272839A1; 2519-EP2272840A1; 2519-EP2272841A1; 2519-EP2272848A1; 2519-EP2272849A1; 2519-EP2272935A1; 2519-EP2272972A1; 2519-EP2272973A1; 2519-EP2274983A1; 2519-EP2275102A1; 2519-EP2275395A2; 2519-EP2275401A1; 2519-EP2275404A1; 2519-EP2275409A1; 2519-EP2275411A2; 2519-EP2275412A1; 2519-EP2275413A1; 2519-EP2275414A1; 2519-EP2276085A1; 2519-EP2277848A1; 2519-EP2277858A1; 2519-EP2277872A1; 2519-EP2277880A1; 2519-EP2280000A1; 2519-EP2280005A1; 2519-EP2280009A1; 2519-EP2281563A1; 2519-EP2281813A1; 2519-EP2281815A1; 2519-EP2281818A1; 2519-EP2281819A1; 2519-EP2281824A1; 2519-EP2284149A1; 2519-EP2284150A2; 2519-EP2284151A2; 2519-EP2284152A2; 2519-EP2284153A2; 2519-EP2284155A2; 2519-EP2284156A2; 2519-EP2284157A1; 2519-EP2284164A2; 2519-EP2284169A1; 2519-EP2284920A1; 2519-EP2286812A1; 2519-EP2286915A2; 2519-EP2287140A2; 2519-EP2287148A2; 2519-EP2287150A2; 2519-EP2287161A1; 2519-EP2287162A1; 2519-EP2287165A2; 2519-EP2287166A2; 2519-EP2287167A1; 2519-EP2289868A1; 2519-EP2289871A1; 2519-EP2289884A1; 2519-EP2289890A1; 2519-EP2289894A2; 2519-EP2292586A2; 2519-EP2292590A2; 2519-EP2292592A1; 2519-EP2292593A2; 2519-EP2292596A2; 2519-EP2292597A1; 2519-EP2292604A2; 2519-EP2292606A1; 2519-EP2292610A1; 2519-EP2292611A1; 2519-EP2292612A2; 2519-EP2292613A1; 2519-EP2292617A1; 2519-EP2292619A1; 2519-EP2292620A2; 2519-EP2292621A1; 2519-EP2292630A1; 2519-EP2295401A2; 2519-EP2295402A2; 2519-EP2295406A1; 2519-EP2295414A1; 2519-EP2295415A1; 2519-EP2295419A2; 2519-EP2295421A1; 2519-EP2295426A1; 2519-EP2295427A1; 2519-EP2295429A1; 2519-EP2295432A1; 2519-EP2295433A2; 2519-EP2295434A2; 2519-EP2295550A2; 2519-EP2298731A1; 2519-EP2298732A1; 2519-EP2298742A1; 2519-EP2298743A1; 2519-EP2298744A2; 2519-EP2298755A1; 2519-EP2298763A1; 2519-EP2298766A1; 2519-EP2298767A1; 2519-EP2298770A1; 2519-EP2298772A1; 2519-EP2298774A1; 2519-EP2298776A1; 2519-EP2298778A1; 2519-EP2298783A1; 2519-EP2298828A1; 2519-EP2299509A1; 2519-EP2300438A1; 2519-EP2301534A1; 2519-EP2301536A1; 2519-EP2301538A1; 2519-EP2301912A2; 2519-EP2301913A1; 2519-EP2301914A1; 2519-EP2301916A2; 2519-EP2301918A1; 2519-EP2301921A1; 2519-EP2301926A1; 2519-EP2301929A1; 2519-EP2301930A1; 2519-EP2301931A1; 2519-EP2301932A1; 2519-EP2301933A1; 2519-EP2301934A1; 2519-EP2301935A1; 2519-EP2301937A1; 2519-EP2301940A1; 2519-EP2301983A1; 2519-EP2302003A1; 2519-EP2302015A1; 2519-EP2305219A1; 2519-EP2305250A1; 2519-EP2305637A2; 2519-EP2305640A2; 2519-EP2305643A1; 2519-EP2305648A1; 2519-EP2305651A1; 2519-EP2305652A2; 2519-EP2305657A2; 2519-EP2305658A1; 2519-EP2305659A1; 2519-EP2305668A1; 2519-EP2305674A1; 2519-EP2305676A1; 2519-EP2305682A1; 2519-EP2305689A1; 2519-EP2305695A2; 2519-EP2305696A2; 2519-EP2305697A2; 2519-EP2305698A2; 2519-EP2305769A2; 2519-EP2305808A1; 2519-EP2308510A1; 2519-EP2308562A2; 2519-EP2308812A2; 2519-EP2308832A1; 2519-EP2308833A2; 2519-EP2308839A1; 2519-EP2308840A1; 2519-EP2308848A1; 2519-EP2308852A1; 2519-EP2308854A1; 2519-EP2308855A1; 2519-EP2308861A1; 2519-EP2308863A1; 2519-EP2308867A2; 2519-EP2308868A1; 2519-EP2308869A1; 2519-EP2308870A2; 2519-EP2308872A1; 2519-EP2308873A1; 2519-EP2308874A1; 2519-EP2308877A1; 2519-EP2308879A1; 2519-EP2308880A1; 2519-EP2308883A1; 2519-EP2309584A1; 2519-EP2311451A1; 2519-EP2311455A1; 2519-EP2311464A1; 2519-EP2311796A1; 2519-EP2311797A1; 2519-EP2311798A1; 2519-EP2311799A1; 2519-EP2311802A1; 2519-EP2311803A1; 2519-EP2311815A1; 2519-EP2311818A1; 2519-EP2311820A1; 2519-EP2311823A1; 2519-EP2311825A1; 2519-EP2311826A2; 2519-EP2311827A1; 2519-EP2311830A1; 2519-EP2311841A1; 2519-EP2311842A2; 2519-EP2314295A1; 2519-EP2314558A1; 2519-EP2314574A1; 2519-EP2314575A1; 2519-EP2314582A1; 2519-EP2314583A1; 2519-EP2314587A1; 2519-EP2315303A1; 2519-EP2315502A1; 2519-EP2316450A1; 2519-EP2316452A1; 2519-EP2316459A1; 2519-EP2316470A2; 2519-EP2316829A1; 2519-EP2316831A1; 2519-EP2316832A1; 2519-EP2316833A1; 2519-EP2316836A1; 2519-EP2316905A1; 2519-EP2316906A2; 2519-EP2371810A1; 2519-EP2371811A2; 2519-EP2371812A1; 2519-EP2371831A1; 2519-EP2372017A1; 2519-EP2372804A1; 2519-EP2377847A1; 2519-EP2377848A1; 2519-EP2378585A1; 2519-EP2380874A2; C01589; M-6056; 59390-EP2270011A1; 59390-EP2272846A1; 59390-EP2305808A1; 59390-EP2308852A1; 59390-EP2371806A1; 59390-EP2371812A1; 142240-EP2270010A1; 142240-EP2292593A2; Imidazole buffer Solution, BioUltra, 1 M in H2O; Q328692; J-200340; Imidazole, for molecular biology, >=99% (titration); F2190-0638; Z1245636370; Imidazole, BioUltra, for molecular biology, >=99.5% (GC); Imidazole, European Pharmacopoeia (EP) Reference Standard; 4286D518-643C-4C69-BCE7-519D073F4992; Imidazole, pharmaceutical impurity standard, >=95.0% (HPLC); Imidazole, United States Pharmacopeia (USP) Reference Standard; InChI=1/C3H4N2/c1-2-5-3-4-1/h1-3H,(H,4,5; Imidazole, anhydrous, free-flowing, Redi-Dri(TM), ACS reagent, >=99%; Imidazole, Pharmaceutical Secondary Standard; Certified Reference Material; Ondansetron impurity E, European Pharmacopoeia (EP) Reference Standard; 5-23-04-00191 (Beilstein Handbook Reference)
Imidazolidinyl urea N,N''-Methylenebis[N'-[3-(hydroxymethyl)-2,5-dioxo-4-imidazolidinyl]urea]; Imidazolidinyl urea; EINECS 254-372-6
Indirubin 3-(1,3-Dihydro-3-oxo-2H-indol-2-ylidene)-1,3-dihydro-2H-indol-2-one; Indirubin; C.I. 73200
Indole-3-acetamide Indoleacetamide; indole-3-acetamide; 879-37-8; 2-(1H-Indol-3-yl)acetamide; 1H-Indole-3-acetamide; 3-Indoleacetamide; Indoleacetamide; (indol-3-yl)acetamide; 3-Indolylacetamide; 1-Indole-3-acetamide; C10H10N2O; NSC 1969; 2-(3-Indolyl)acetamide; UNII-O9SEW65XW3; (1H-indol-3-yl)acetamide; Indole-3-acetamide (8CI); O9SEW65XW3; Indole-3-acetamide (6CI,8CI); ZOAMBXDOGPRZLP-UHFFFAOYSA-N; 2-indol-3-ylacetamide; TSR; EINECS 212-904-4; PubChem7350; ACMC-1BKDN; 1H-Indol-3-ylacetamide; 1H-indol-3-yl-acetamide; 3-INDOLE ACETAMIDE; bmse000696; Indole-3-acetamide, 98%; Oprea1_704903; SCHEMBL40822; KSC449A4B; SCHEMBL8082815; 3-Indolylacetamide; NSC 1969; 2-(1H-indol-3-yl)-acetamide; CHEBI:16031; CTK3E9040; KS-00000FSM; ZOAMBXDOGPRZLP-UHFFFAOYSA-; DTXSID60236686; NSC1969; 2-(1H-Indol-3-yl)acetamide #; HMS1740A02; HMS3604E11; ZINC409269; ACT07017; BCP27037; NSC-1969; AM1212; ANW-38925; CI-032; MFCD00005641; s5610; SBB055978; AKOS001129741; CM10935; CS-W017500; DB08652; FS-2701; HY-W016784; MCULE-8683047927; RTC-020185; SB15031; TRA0069847; AC-23418; AK-43401; BR-43401; SC-46456; SY014237; AB0010861; DB-011565; TC-020185; FT-0615869; I0668; ST24030782; ST51006791; C02693; I-0900; 879I378; Q27097844; 99FEA035-A073-4863-9F14-923310E3BC45; 879-06-1; IAM; InChI=1/C10H10N2O/c11-10(13)5-7-6-12-9-4-2-1-3-8(7)9/h1-4,6,12H,5H2,(H2,11,13); EINECS 212-904-4
Indole-3-carbinol 1H-Indole-3-methanol; Indole-3-carbinol; 700-06-1; 3-Indolemethanol; INDOLE-3-METHANOL; (1H-Indol-3-yl)methanol; 1H-indol-3-ylmethanol; 1H-Indole-3-methanol; 3-Hydroxymethylindole; 3-Indolylcarbinol; Indinol; 3-(Hydroxymethyl)indole; 3-Indole methanol; Indole 3 carbinol; (1H-Indol-3-yl)-methanol; CCRIS 3261; UNII-C11E72455F; EINECS 211-836-2; MFCD00005632; I3C; NSC 525801; BRN 0121323; AI3-60090; CHEBI:24814; IVYPNXXAYMYVSP-UHFFFAOYSA-N; Prevention 4 (indole-3-carbinol); C11E72455F; NSC-525801; NCGC00090701-06; indol-3-ylmethan-1-ol; I0496; Indole-3-carbinol, 97%; SMR000385784; I3C cpd; 1H-Indol-3-Yl-Methanol; 3-Indolecarbinol; 3-Indolylmethanol; indole-3-carbinole; zlchem 356; PubChem7265; H-indol-3-ylmethanol; 3-hydroxymethyl indole; Spectrum2_001710; Spectrum3_001973; ACMC-209oc7; DSSTox_CID_11458; DSSTox_RID_78876; DSSTox_GSID_31458; BSPBio_003573; MLS001333161; MLS001333162; SCHEMBL195520; SPECTRUM1505320; SPBio_001700; CHEMBL155625; 1H-Indole-3-methanol (9CI); DTXSID7031458; CTK5D1676; GTPL10047; KBio3_002949; ZLC0198; HMS1789O22; HMS2235E10; HMS3369B02; HMS3651I18; HMS3749E07; ZINC158743; ACN-S002804; ACT03591; BCP00087; HY-N0170; INDOLE-3-CARBINOL (I3C); KS-000008ZG; Tox21_400055; 9344AF; AM1155; ANW-35813; CCG-38786; HSCI1_000097; NSC525801; s2313; SBB004095; AKOS001075120; AC-7583; CS-7780; DB12881; GS-0916; LS-2173; LS20980; MCULE-6344603304; RTC-020178; SB14958; SDCCGMLS-0065970.P001; SDCCGMLS-0065970.P002; VI30396; Indole-3-methanol (Indole-3-carbinol); SMP2_000172; TRA-0190502; NCGC00090701-01; NCGC00090701-02; NCGC00090701-03; NCGC00090701-04; NCGC00090701-05; NCGC00090701-07; AK-53373; BR-53373; CAS-700-06-1; SC-06380; SY015976; AB0008317; AB1009801; DB-011567; ST2402099; 4CH-018038; A9256; FT-0615875; ST50308202; SW219849-1; 00I061; I-2100; M-3233; A836732; SR-01000838318; Q1770257; SR-01000838318-3; BRD-K01815685-001-02-3; BRD-K01815685-001-07-2; Z85923165; Indole-3-carbinol; 5-21-03-00045 (Beilstein Handbook Reference)
Indomethacin 1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid; Indomethacin; 5-22-05-00239 (Beilstein Handbook Reference)
Inosine inosine; 58-63-9; Hypoxanthosine; Ribonosine; Atorel; Oxiamin; Trophicardyl; Selfer; Pantholic-L; Panholic-L; Hypoxanthine riboside; beta-Inosine; Hypoxanthine D-riboside; Hypoxanthine ribonucleoside; (-)-Inosine; 9-beta-D-Ribofuranosylhypoxanthine; Hypoxanthine nucleoside; INO 495; Inosina; Inosinum; Inosie; iso-prinosine; Inosine [INN:JAN]; Inosinum [INN-Latin]; Inosina [INN-Spanish]; hypoxanthine-ribose; NSC 20262; Hypoxanthine, 9-beta-D-ribofuranosyl-; Inosin; AI3-52241; Hypoxanthine-9-beta-D-ribofuranoside; beta-D-Ribofuranoside, hypoxanthine-9; UNII-5A614L51CT; HXR; EINECS 200-390-4; Hypoxanthine 9-beta-D-ribofuranoside; MFCD00066770; MLS000028518; CHEBI:17596; UGQMRVRMYYASKQ-KQYNXXCUSA-N; INO; 5A614L51CT; 9.beta.-D-Ribofuranosylhypoxanthine; 9-beta-D-ribofuranosyl-9H-purin-6-ol; Inosine, 99%; SMR000058316; DSSTox_CID_25993; DSSTox_RID_81278; DSSTox_GSID_45993; 1,9-Dihydro-9-beta-D-ribofuranosyl-6H-purin-6-one; .beta.-Inosine; C10H12N4O5; 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one; 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-3H-purin-6-one; CAS-58-63-9; SR-01000721862; Catacol; NSC20262; 9-.beta.-D-Ribofuranosylhypoxanthine; NSC-20262; 3h-inosine; D-Inosine; 2ada; 2fqw; .beta.-D-Ribofuranoside, hypoxanthine-9; NCGC00095787-01; Hypoxanthine, 9-.beta.-D-ribofuranosyl-; Inosine,(S); Inotin (TN); Inosine (JAN/INN); PubChem14189; 1a4m; Inosine (8CI,9CI); Opera_ID_1628; bmse000098; bmse000888; bmse000978; cid_6021; CHEMBL1556; SCHEMBL15804; KBioGR_002560; KBioSS_002569; KSC269S6L; ARONIS24558; GTPL4554; 9-b-D-Ribofuranosylhypoxanthine; Hypoxanthine-9-D-ribofuranoside; Inosine, >=99% (HPLC); DTXSID2045993; 9beta-D-Ribofuranosylhypoxanthine; BDBM22104; CTK1G9965; KBio2_002560; KBio2_005128; KBio2_007696; KBio3_003038; 9-b-D-ribofuranosyl-Hypoxanthine; cMAP_000084; HMS2235I17; Hypoxanthine-9-delta-ribofuranoside; 9-beta-D-ribofuranosyl-Hypoxanthine; HY-N0092; ZINC8855117; 9beta-delta-Ribofuranosylhypoxanthine; Tox21_111522; ANW-33000; BDBM50366815; beta-D-Ribofuranoside hypoxanthine-9; hypoxanthine-9 beta-D-Ribofuranoside; s2442; 9-beta-delta-Ribofuranosylhypoxanthine; AKOS015969695; AKOS015995607; AKOS024462561; Tox21_111522_1; 9-beta-delta-ribofuranosyl-Hypoxanthine; AM83935; CS-5845; DB04335; MCULE-3095132846; RTR-037177; (2R,3R,4S,5R)-2-(6-Hydroxy-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one; 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-1H-purin-6-one; beta-delta-Ribofuranoside hypoxanthine-9; Hypoxanthine 9-beta-delta-ribofuranoside; hypoxanthine-9 beta-delta-Ribofuranoside; Hypoxanthine-9-beta-delta-ribofuranoside; SMP1_000165; NCGC00096119-02; NCGC00096119-03; AS-11754; LS-84000; 9-(beta-D-ribofuranosyl)-9H-purin-6-ol; AB0066076; AB1000320; DB-029916; TR-037177; FT-0627217; I0037; A-8687; C00294; D00054; J10406; 1,9-dihydro-9-b-D-ribofuranosyl-6H-Purin-6-one; Q422564; SR-01000721862-2; SR-01000721862-3; AC89F8E4-FD89-45EE-8B41-94DFC07AB42F; BRD-K79612754-001-21-7; 1,9-Dihydro-9-beta-delta-ribofuranosyl-6H-purin-6-one; 6H-Purin-6-one, 1,9-dihydro-9-beta-D-ribofuranosyl-; 9-beta-D-Ribofuranosyl-1,9-dihydro-6H-purin-6-one (Inosine); (2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-hydroxy-9H-purin-9-yl)tetrahydrofuran-3,4-diol; 9-(3,4-DIHYDROXY-5-HYDROXYMETHYL-TETRAHYDRO-FURAN-2-YL)-1,9-DIHYDRO-PURIN-6-ONE; 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-purin-6-one; 9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-purin-6(9H)-one; InChI=1/C10H12N4O5/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18/h2-4,6-7,10,15-17H,1H2,(H,11,12,18)/t4-,6-,7-,10-/m1/s; AI3-52241